UPCS_Ranking

Array ( [links] => Array ( [#theme] => links__node [#pre_render] => Array ( [0] => drupal_pre_render_links ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) [node] => Array ( [#theme] => links__node__node [#links] => Array ( [node-readmore] => Array ( [title] => Read more about UPCS_Ranking [href] => node/127218 [html] => 1 [attributes] => Array ( [rel] => tag [title] => UPCS_Ranking ) ) ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) ) ) [field_testo_opz] => Array ( [#theme] => field [#weight] => 31 [#title] => testo [#access] => 1 [#label_display] => hidden [#view_mode] => teaser [#language] => und [#field_name] => field_testo_opz [#field_type] => text_long [#field_translatable] => 0 [#entity_type] => node [#bundle] => testo_opzionale [#object] => stdClass Object ( [vid] => 516872 [uid] => 18875 [title] => UPCS_Ranking [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 127218 [type] => testo_opzionale [language] => it [created] => 1769687674 [changed] => 1769688087 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1769688087 [revision_uid] => 18875 [field_testo_opz] => Array ( [und] => Array ( [0] => Array ( [value] =>

Pagina a cura di:

Ranking Unit

Settore Coordinamento Dati statistici e Ranking
UPCS - Ufficio Pianificazione e Controllo Strategico
ACOsQ - Area Controllo strategico e Qualità

ranking@unipd.it

[format] => 2 [safe_value] =>

Pagina a cura di:

Ranking Unit

Settore Coordinamento Dati statistici e Ranking
UPCS - Ufficio Pianificazione e Controllo Strategico
ACOsQ - Area Controllo strategico e Qualità

ranking@unipd.it

) ) ) [name] => ranking [picture] => 0 [data] => b:0; [num_revisions] => 2 [current_revision_id] => 516872 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] =>

Pagina a cura di:

Ranking Unit

Settore Coordinamento Dati statistici e Ranking
UPCS - Ufficio Pianificazione e Controllo Strategico
ACOsQ - Area Controllo strategico e Qualità

ranking@unipd.it

[format] => 2 [safe_value] =>

Pagina a cura di:

Ranking Unit

Settore Coordinamento Dati statistici e Ranking
UPCS - Ufficio Pianificazione e Controllo Strategico
ACOsQ - Area Controllo strategico e Qualità

ranking@unipd.it

) ) [#formatter] => text_default [0] => Array ( [#markup] =>

Pagina a cura di:

Ranking Unit

Settore Coordinamento Dati statistici e Ranking
UPCS - Ufficio Pianificazione e Controllo Strategico
ACOsQ - Area Controllo strategico e Qualità

ranking@unipd.it

) ) )

GIORNATA DEDICATA GLI INTERNATI MILITARI ITALIANI (IMI). Sabato 31 gennaio: una mostra e uno spettacolo teatrale

Array ( [field_luogo_area_stampa] => Array ( [#theme] => field [#weight] => -4 [#title] => Luogo [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_luogo_area_stampa [#field_type] => text_long [#field_translatable] => 0 [#entity_type] => node [#bundle] => allegato_area_stampa [#object] => stdClass Object ( [vid] => 516866 [uid] => 8835 [title] => GIORNATA DEDICATA GLI INTERNATI MILITARI ITALIANI (IMI). Sabato 31 gennaio: una mostra e uno spettacolo teatrale [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 127217 [type] => allegato_area_stampa [language] => und [created] => 1769687138 [changed] => 1769687138 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1769687138 [revision_uid] => 8835 [body] => Array ( ) [field_allegato_area_stampa] => Array ( [und] => Array ( [0] => Array ( [fid] => 145768 [uid] => 8835 [filename] => Comunicato _GIORNATA DEDICATA GLI INTERNATI MILITARI ITALIANI - IMI.pdf [uri] => public://Comunicato _GIORNATA DEDICATA GLI INTERNATI MILITARI ITALIANI - IMI.pdf [filemime] => application/pdf [filesize] => 224061 [status] => 1 [timestamp] => 1769687138 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [field_all_imm_area_stampa] => Array ( ) [field_data_area_stampa] => Array ( [und] => Array ( [0] => Array ( [value] => 2026-01-29 00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => datetime ) ) ) [field_luogo_area_stampa] => Array ( [und] => Array ( [0] => Array ( [value] => Padova [format] => [safe_value] => Padova ) ) ) [name] => stampa [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 516866 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => Padova [format] => [safe_value] => Padova ) ) [#formatter] => text_default [0] => Array ( [#markup] => Padova ) ) [field_data_area_stampa] => Array ( [#theme] => field [#weight] => -3 [#title] => Data [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_data_area_stampa [#field_type] => datetime [#field_translatable] => 0 [#entity_type] => node [#bundle] => allegato_area_stampa [#object] => stdClass Object ( [vid] => 516866 [uid] => 8835 [title] => GIORNATA DEDICATA GLI INTERNATI MILITARI ITALIANI (IMI). Sabato 31 gennaio: una mostra e uno spettacolo teatrale [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 127217 [type] => allegato_area_stampa [language] => und [created] => 1769687138 [changed] => 1769687138 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1769687138 [revision_uid] => 8835 [body] => Array ( ) [field_allegato_area_stampa] => Array ( [und] => Array ( [0] => Array ( [fid] => 145768 [uid] => 8835 [filename] => Comunicato _GIORNATA DEDICATA GLI INTERNATI MILITARI ITALIANI - IMI.pdf [uri] => public://Comunicato _GIORNATA DEDICATA GLI INTERNATI MILITARI ITALIANI - IMI.pdf [filemime] => application/pdf [filesize] => 224061 [status] => 1 [timestamp] => 1769687138 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [field_all_imm_area_stampa] => Array ( ) [field_data_area_stampa] => Array ( [und] => Array ( [0] => Array ( [value] => 2026-01-29 00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => datetime ) ) ) [field_luogo_area_stampa] => Array ( [und] => Array ( [0] => Array ( [value] => Padova [format] => [safe_value] => Padova ) ) ) [name] => stampa [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 516866 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => 2026-01-29 00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => datetime ) ) [#formatter] => date_default [0] => Array ( [#markup] => Gio, 29/01/2026 ) ) [field_allegato_area_stampa] => Array ( [#theme] => field [#weight] => -2 [#title] => Allegato [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_allegato_area_stampa [#field_type] => file [#field_translatable] => 0 [#entity_type] => node [#bundle] => allegato_area_stampa [#object] => stdClass Object ( [vid] => 516866 [uid] => 8835 [title] => GIORNATA DEDICATA GLI INTERNATI MILITARI ITALIANI (IMI). Sabato 31 gennaio: una mostra e uno spettacolo teatrale [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 127217 [type] => allegato_area_stampa [language] => und [created] => 1769687138 [changed] => 1769687138 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1769687138 [revision_uid] => 8835 [body] => Array ( ) [field_allegato_area_stampa] => Array ( [und] => Array ( [0] => Array ( [fid] => 145768 [uid] => 8835 [filename] => Comunicato _GIORNATA DEDICATA GLI INTERNATI MILITARI ITALIANI - IMI.pdf [uri] => public://Comunicato _GIORNATA DEDICATA GLI INTERNATI MILITARI ITALIANI - IMI.pdf [filemime] => application/pdf [filesize] => 224061 [status] => 1 [timestamp] => 1769687138 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [field_all_imm_area_stampa] => Array ( ) [field_data_area_stampa] => Array ( [und] => Array ( [0] => Array ( [value] => 2026-01-29 00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => datetime ) ) ) [field_luogo_area_stampa] => Array ( [und] => Array ( [0] => Array ( [value] => Padova [format] => [safe_value] => Padova ) ) ) [name] => stampa [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 516866 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [fid] => 145768 [uid] => 8835 [filename] => Comunicato _GIORNATA DEDICATA GLI INTERNATI MILITARI ITALIANI - IMI.pdf [uri] => public://Comunicato _GIORNATA DEDICATA GLI INTERNATI MILITARI ITALIANI - IMI.pdf [filemime] => application/pdf [filesize] => 224061 [status] => 1 [timestamp] => 1769687138 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) [#formatter] => file_default [0] => Array ( [#theme] => file_link [#file] => stdClass Object ( [fid] => 145768 [uid] => 8835 [filename] => Comunicato _GIORNATA DEDICATA GLI INTERNATI MILITARI ITALIANI - IMI.pdf [uri] => public://Comunicato _GIORNATA DEDICATA GLI INTERNATI MILITARI ITALIANI - IMI.pdf [filemime] => application/pdf [filesize] => 224061 [status] => 1 [timestamp] => 1769687138 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [links] => Array ( [#theme] => links__node [#pre_render] => Array ( [0] => drupal_pre_render_links ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) [node] => Array ( [#theme] => links__node__node [#links] => Array ( [node-readmore] => Array ( [title] => Read more about GIORNATA DEDICATA GLI INTERNATI MILITARI ITALIANI (IMI). Sabato 31 gennaio: una mostra e uno spettacolo teatrale [href] => node/127217 [html] => 1 [attributes] => Array ( [rel] => tag [title] => GIORNATA DEDICATA GLI INTERNATI MILITARI ITALIANI (IMI). Sabato 31 gennaio: una mostra e uno spettacolo teatrale ) ) ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) ) ) )

SPORT, STUDIO E BENESSERE ALL'UNIVERSITÀ DI PADOVA Sabato 31 gennaio Ferdinando "Fefè" De Giorgi ospite in Sala dei Giganti

Array ( [field_luogo_area_stampa] => Array ( [#theme] => field [#weight] => -4 [#title] => Luogo [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_luogo_area_stampa [#field_type] => text_long [#field_translatable] => 0 [#entity_type] => node [#bundle] => allegato_area_stampa [#object] => stdClass Object ( [vid] => 516865 [uid] => 8835 [title] => SPORT, STUDIO E BENESSERE ALL'UNIVERSITÀ DI PADOVA Sabato 31 gennaio Ferdinando "Fefè" De Giorgi ospite in Sala dei Giganti [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 127216 [type] => allegato_area_stampa [language] => und [created] => 1769686800 [changed] => 1769686800 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1769686800 [revision_uid] => 8835 [body] => Array ( ) [field_allegato_area_stampa] => Array ( [und] => Array ( [0] => Array ( [fid] => 145767 [uid] => 8835 [filename] => Comunicato _SPORT STUDIO E BENESSERE ALL_UNIVERSITA DI PADOVA.pdf [uri] => public://Comunicato _SPORT STUDIO E BENESSERE ALL_UNIVERSITA DI PADOVA.pdf [filemime] => application/pdf [filesize] => 191218 [status] => 1 [timestamp] => 1769686800 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [field_all_imm_area_stampa] => Array ( ) [field_data_area_stampa] => Array ( [und] => Array ( [0] => Array ( [value] => 2026-01-29 00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => datetime ) ) ) [field_luogo_area_stampa] => Array ( [und] => Array ( [0] => Array ( [value] => Padova [format] => [safe_value] => Padova ) ) ) [name] => stampa [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 516865 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => Padova [format] => [safe_value] => Padova ) ) [#formatter] => text_default [0] => Array ( [#markup] => Padova ) ) [field_data_area_stampa] => Array ( [#theme] => field [#weight] => -3 [#title] => Data [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_data_area_stampa [#field_type] => datetime [#field_translatable] => 0 [#entity_type] => node [#bundle] => allegato_area_stampa [#object] => stdClass Object ( [vid] => 516865 [uid] => 8835 [title] => SPORT, STUDIO E BENESSERE ALL'UNIVERSITÀ DI PADOVA Sabato 31 gennaio Ferdinando "Fefè" De Giorgi ospite in Sala dei Giganti [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 127216 [type] => allegato_area_stampa [language] => und [created] => 1769686800 [changed] => 1769686800 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1769686800 [revision_uid] => 8835 [body] => Array ( ) [field_allegato_area_stampa] => Array ( [und] => Array ( [0] => Array ( [fid] => 145767 [uid] => 8835 [filename] => Comunicato _SPORT STUDIO E BENESSERE ALL_UNIVERSITA DI PADOVA.pdf [uri] => public://Comunicato _SPORT STUDIO E BENESSERE ALL_UNIVERSITA DI PADOVA.pdf [filemime] => application/pdf [filesize] => 191218 [status] => 1 [timestamp] => 1769686800 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [field_all_imm_area_stampa] => Array ( ) [field_data_area_stampa] => Array ( [und] => Array ( [0] => Array ( [value] => 2026-01-29 00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => datetime ) ) ) [field_luogo_area_stampa] => Array ( [und] => Array ( [0] => Array ( [value] => Padova [format] => [safe_value] => Padova ) ) ) [name] => stampa [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 516865 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => 2026-01-29 00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => datetime ) ) [#formatter] => date_default [0] => Array ( [#markup] => Gio, 29/01/2026 ) ) [field_allegato_area_stampa] => Array ( [#theme] => field [#weight] => -2 [#title] => Allegato [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_allegato_area_stampa [#field_type] => file [#field_translatable] => 0 [#entity_type] => node [#bundle] => allegato_area_stampa [#object] => stdClass Object ( [vid] => 516865 [uid] => 8835 [title] => SPORT, STUDIO E BENESSERE ALL'UNIVERSITÀ DI PADOVA Sabato 31 gennaio Ferdinando "Fefè" De Giorgi ospite in Sala dei Giganti [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 127216 [type] => allegato_area_stampa [language] => und [created] => 1769686800 [changed] => 1769686800 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1769686800 [revision_uid] => 8835 [body] => Array ( ) [field_allegato_area_stampa] => Array ( [und] => Array ( [0] => Array ( [fid] => 145767 [uid] => 8835 [filename] => Comunicato _SPORT STUDIO E BENESSERE ALL_UNIVERSITA DI PADOVA.pdf [uri] => public://Comunicato _SPORT STUDIO E BENESSERE ALL_UNIVERSITA DI PADOVA.pdf [filemime] => application/pdf [filesize] => 191218 [status] => 1 [timestamp] => 1769686800 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [field_all_imm_area_stampa] => Array ( ) [field_data_area_stampa] => Array ( [und] => Array ( [0] => Array ( [value] => 2026-01-29 00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => datetime ) ) ) [field_luogo_area_stampa] => Array ( [und] => Array ( [0] => Array ( [value] => Padova [format] => [safe_value] => Padova ) ) ) [name] => stampa [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 516865 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [fid] => 145767 [uid] => 8835 [filename] => Comunicato _SPORT STUDIO E BENESSERE ALL_UNIVERSITA DI PADOVA.pdf [uri] => public://Comunicato _SPORT STUDIO E BENESSERE ALL_UNIVERSITA DI PADOVA.pdf [filemime] => application/pdf [filesize] => 191218 [status] => 1 [timestamp] => 1769686800 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) [#formatter] => file_default [0] => Array ( [#theme] => file_link [#file] => stdClass Object ( [fid] => 145767 [uid] => 8835 [filename] => Comunicato _SPORT STUDIO E BENESSERE ALL_UNIVERSITA DI PADOVA.pdf [uri] => public://Comunicato _SPORT STUDIO E BENESSERE ALL_UNIVERSITA DI PADOVA.pdf [filemime] => application/pdf [filesize] => 191218 [status] => 1 [timestamp] => 1769686800 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [links] => Array ( [#theme] => links__node [#pre_render] => Array ( [0] => drupal_pre_render_links ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) [node] => Array ( [#theme] => links__node__node [#links] => Array ( [node-readmore] => Array ( [title] => Read more about SPORT, STUDIO E BENESSERE ALL'UNIVERSITÀ DI PADOVA Sabato 31 gennaio Ferdinando "Fefè" De Giorgi ospite in Sala dei Giganti [href] => node/127216 [html] => 1 [attributes] => Array ( [rel] => tag [title] => SPORT, STUDIO E BENESSERE ALL'UNIVERSITÀ DI PADOVA Sabato 31 gennaio Ferdinando "Fefè" De Giorgi ospite in Sala dei Giganti ) ) ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) ) ) )

Clhep: dall’eccellenza accademica a nuove terapie contro il cancro. Dalla collaborazione con l’Università di Padova, Bio4Dreams annuncia la nascita dello spin-off Clhep e l’avvio dell’incubazione

Array ( [field_luogo_area_stampa] => Array ( [#theme] => field [#weight] => -4 [#title] => Luogo [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_luogo_area_stampa [#field_type] => text_long [#field_translatable] => 0 [#entity_type] => node [#bundle] => allegato_area_stampa [#object] => stdClass Object ( [vid] => 516864 [uid] => 8835 [title] => Clhep: dall’eccellenza accademica a nuove terapie contro il cancro. Dalla collaborazione con l’Università di Padova, Bio4Dreams annuncia la nascita dello spin-off Clhep e l’avvio dell’incubazione [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 127215 [type] => allegato_area_stampa [language] => und [created] => 1769686610 [changed] => 1769686610 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1769686610 [revision_uid] => 8835 [body] => Array ( ) [field_allegato_area_stampa] => Array ( [und] => Array ( [0] => Array ( [fid] => 145766 [uid] => 8835 [filename] => 2026-01-29_Costituzione e incubazione Clhep_finale_rev.pdf [uri] => public://2026-01-29_Costituzione e incubazione Clhep_finale_rev.pdf [filemime] => application/pdf [filesize] => 252298 [status] => 1 [timestamp] => 1769686610 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [field_all_imm_area_stampa] => Array ( ) [field_data_area_stampa] => Array ( [und] => Array ( [0] => Array ( [value] => 2026-01-29 00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => datetime ) ) ) [field_luogo_area_stampa] => Array ( [und] => Array ( [0] => Array ( [value] => Padova [format] => [safe_value] => Padova ) ) ) [name] => stampa [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 516864 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => Padova [format] => [safe_value] => Padova ) ) [#formatter] => text_default [0] => Array ( [#markup] => Padova ) ) [field_data_area_stampa] => Array ( [#theme] => field [#weight] => -3 [#title] => Data [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_data_area_stampa [#field_type] => datetime [#field_translatable] => 0 [#entity_type] => node [#bundle] => allegato_area_stampa [#object] => stdClass Object ( [vid] => 516864 [uid] => 8835 [title] => Clhep: dall’eccellenza accademica a nuove terapie contro il cancro. Dalla collaborazione con l’Università di Padova, Bio4Dreams annuncia la nascita dello spin-off Clhep e l’avvio dell’incubazione [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 127215 [type] => allegato_area_stampa [language] => und [created] => 1769686610 [changed] => 1769686610 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1769686610 [revision_uid] => 8835 [body] => Array ( ) [field_allegato_area_stampa] => Array ( [und] => Array ( [0] => Array ( [fid] => 145766 [uid] => 8835 [filename] => 2026-01-29_Costituzione e incubazione Clhep_finale_rev.pdf [uri] => public://2026-01-29_Costituzione e incubazione Clhep_finale_rev.pdf [filemime] => application/pdf [filesize] => 252298 [status] => 1 [timestamp] => 1769686610 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [field_all_imm_area_stampa] => Array ( ) [field_data_area_stampa] => Array ( [und] => Array ( [0] => Array ( [value] => 2026-01-29 00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => datetime ) ) ) [field_luogo_area_stampa] => Array ( [und] => Array ( [0] => Array ( [value] => Padova [format] => [safe_value] => Padova ) ) ) [name] => stampa [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 516864 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => 2026-01-29 00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => datetime ) ) [#formatter] => date_default [0] => Array ( [#markup] => Gio, 29/01/2026 ) ) [field_allegato_area_stampa] => Array ( [#theme] => field [#weight] => -2 [#title] => Allegato [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_allegato_area_stampa [#field_type] => file [#field_translatable] => 0 [#entity_type] => node [#bundle] => allegato_area_stampa [#object] => stdClass Object ( [vid] => 516864 [uid] => 8835 [title] => Clhep: dall’eccellenza accademica a nuove terapie contro il cancro. Dalla collaborazione con l’Università di Padova, Bio4Dreams annuncia la nascita dello spin-off Clhep e l’avvio dell’incubazione [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 127215 [type] => allegato_area_stampa [language] => und [created] => 1769686610 [changed] => 1769686610 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1769686610 [revision_uid] => 8835 [body] => Array ( ) [field_allegato_area_stampa] => Array ( [und] => Array ( [0] => Array ( [fid] => 145766 [uid] => 8835 [filename] => 2026-01-29_Costituzione e incubazione Clhep_finale_rev.pdf [uri] => public://2026-01-29_Costituzione e incubazione Clhep_finale_rev.pdf [filemime] => application/pdf [filesize] => 252298 [status] => 1 [timestamp] => 1769686610 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [field_all_imm_area_stampa] => Array ( ) [field_data_area_stampa] => Array ( [und] => Array ( [0] => Array ( [value] => 2026-01-29 00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => datetime ) ) ) [field_luogo_area_stampa] => Array ( [und] => Array ( [0] => Array ( [value] => Padova [format] => [safe_value] => Padova ) ) ) [name] => stampa [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 516864 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [fid] => 145766 [uid] => 8835 [filename] => 2026-01-29_Costituzione e incubazione Clhep_finale_rev.pdf [uri] => public://2026-01-29_Costituzione e incubazione Clhep_finale_rev.pdf [filemime] => application/pdf [filesize] => 252298 [status] => 1 [timestamp] => 1769686610 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) [#formatter] => file_default [0] => Array ( [#theme] => file_link [#file] => stdClass Object ( [fid] => 145766 [uid] => 8835 [filename] => 2026-01-29_Costituzione e incubazione Clhep_finale_rev.pdf [uri] => public://2026-01-29_Costituzione e incubazione Clhep_finale_rev.pdf [filemime] => application/pdf [filesize] => 252298 [status] => 1 [timestamp] => 1769686610 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [links] => Array ( [#theme] => links__node [#pre_render] => Array ( [0] => drupal_pre_render_links ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) [node] => Array ( [#theme] => links__node__node [#links] => Array ( [node-readmore] => Array ( [title] => Read more about Clhep: dall’eccellenza accademica a nuove terapie contro il cancro. Dalla collaborazione con l’Università di Padova, Bio4Dreams annuncia la nascita dello spin-off Clhep e l’avvio dell’incubazione [href] => node/127215 [html] => 1 [attributes] => Array ( [rel] => tag [title] => Clhep: dall’eccellenza accademica a nuove terapie contro il cancro. Dalla collaborazione con l’Università di Padova, Bio4Dreams annuncia la nascita dello spin-off Clhep e l’avvio dell’incubazione ) ) ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) ) ) )

Riconoscimenti - Percorsi abilitanti di formazione iniziale degli insegnanti

Array ( [field_titolo_frontend] => Array ( [#theme] => field [#weight] => -4 [#title] => Titolo frontend [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_titolo_frontend [#field_type] => text_long [#field_translatable] => 0 [#entity_type] => node [#bundle] => elemento_accordion [#object] => stdClass Object ( [vid] => 516855 [uid] => 29556 [title] => Riconoscimenti - Percorsi abilitanti di formazione iniziale degli insegnanti [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 127214 [type] => elemento_accordion [language] => it [created] => 1769683023 [changed] => 1774517613 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1774517613 [revision_uid] => 29556 [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_accordion_state] => Array ( [und] => Array ( [0] => Array ( [value] => chiuso ) ) ) [field_allegato_element] => Array ( [und] => Array ( [0] => Array ( [nid] => 127526 [access] => 1 [node] => stdClass Object ( [vid] => 518122 [uid] => 32 [title] => Insegnamenti riconoscibili - Riconoscimenti - Informativa riconoscimenti CFU [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 127526 [type] => allegato [language] => it [created] => 1771228011 [changed] => 1771228011 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1771228011 [revision_uid] => 32 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Insegnamenti riconoscibili [format] => [safe_value] => Insegnamenti riconoscibili ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 146201 [uid] => 32 [filename] => Insegnamenti riconoscibili 2025_2026.pdf [uri] => public://2026/Insegnamenti riconoscibili 2025_2026.pdf [filemime] => application/pdf [filesize] => 313645 [status] => 1 [timestamp] => 1771228005 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2690 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => stefano.zampieri [picture] => 0 [data] => a:2:{s:13:"form_build_id";s:48:"form-WsCySmos4vAVlyFhG6gU5T7knfAyqco8LxlocSU_yIA";s:14:"wysiwyg_status";a:1:{i:1;i:1;}} [num_revisions] => 1 [current_revision_id] => 518122 [is_current] => 1 [is_pending] => [revision_moderation] => ) ) [1] => Array ( [nid] => 127212 [access] => 1 [node] => stdClass Object ( [vid] => 516853 [uid] => 29556 [title] => Riconoscimenti - Informativa riconoscimenti CFU [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 127212 [type] => allegato [language] => it [created] => 1769682945 [changed] => 1771405077 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1771405077 [revision_uid] => 29556 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Informativa riconoscimenti CFU [format] => [safe_value] => Informativa riconoscimenti CFU ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 146323 [uid] => 29556 [filename] => Informativa riconoscimenti CFU agg.pdf [uri] => public://2026/Informativa riconoscimenti CFU agg.pdf [filemime] => application/pdf [filesize] => 309961 [status] => 1 [timestamp] => 1771405072 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2690 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => jessica.russo [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 516853 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) ) [2] => Array ( [nid] => 127213 [access] => 1 [node] => stdClass Object ( [vid] => 516854 [uid] => 29556 [title] => Riconoscimenti - Tabella convalida 24 CFU 2025-26 [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 127213 [type] => allegato [language] => it [created] => 1769683015 [changed] => 1769683015 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1769683015 [revision_uid] => 29556 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Tabella convalida 24 CFU 2025-26 [format] => [safe_value] => Tabella convalida 24 CFU 2025-26 ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 145763 [uid] => 29556 [filename] => Tabella convalida 24 CFU 2025_2026.pdf [uri] => public://2026/Tabella convalida 24 CFU 2025_2026.pdf [filemime] => application/pdf [filesize] => 129664 [status] => 1 [timestamp] => 1769683009 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2690 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => jessica.russo [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 516854 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) ) ) ) [field_outline_level] => Array ( [und] => Array ( [0] => Array ( [value] => h3 ) ) ) [field_titolo_frontend] => Array ( [und] => Array ( [0] => Array ( [value] => Riconoscimenti [format] => [safe_value] => Riconoscimenti ) ) ) [name] => jessica.russo [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 516855 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => Riconoscimenti [format] => [safe_value] => Riconoscimenti ) ) [#formatter] => text_default [0] => Array ( [#markup] => Riconoscimenti ) ) [field_allegato_element] => Array ( [#theme] => field [#weight] => -2 [#title] => Elemento allegato [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_allegato_element [#field_type] => node_reference [#field_translatable] => 0 [#entity_type] => node [#bundle] => elemento_accordion [#object] => stdClass Object ( [vid] => 516855 [uid] => 29556 [title] => Riconoscimenti - Percorsi abilitanti di formazione iniziale degli insegnanti [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 127214 [type] => elemento_accordion [language] => it [created] => 1769683023 [changed] => 1774517613 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1774517613 [revision_uid] => 29556 [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_accordion_state] => Array ( [und] => Array ( [0] => Array ( [value] => chiuso ) ) ) [field_allegato_element] => Array ( [und] => Array ( [0] => Array ( [nid] => 127526 [access] => 1 [node] => stdClass Object ( [vid] => 518122 [uid] => 32 [title] => Insegnamenti riconoscibili - Riconoscimenti - Informativa riconoscimenti CFU [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 127526 [type] => allegato [language] => it [created] => 1771228011 [changed] => 1771228011 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1771228011 [revision_uid] => 32 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Insegnamenti riconoscibili [format] => [safe_value] => Insegnamenti riconoscibili ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 146201 [uid] => 32 [filename] => Insegnamenti riconoscibili 2025_2026.pdf [uri] => public://2026/Insegnamenti riconoscibili 2025_2026.pdf [filemime] => application/pdf [filesize] => 313645 [status] => 1 [timestamp] => 1771228005 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2690 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => stefano.zampieri [picture] => 0 [data] => a:2:{s:13:"form_build_id";s:48:"form-WsCySmos4vAVlyFhG6gU5T7knfAyqco8LxlocSU_yIA";s:14:"wysiwyg_status";a:1:{i:1;i:1;}} [num_revisions] => 1 [current_revision_id] => 518122 [is_current] => 1 [is_pending] => [revision_moderation] => ) ) [1] => Array ( [nid] => 127212 [access] => 1 [node] => stdClass Object ( [vid] => 516853 [uid] => 29556 [title] => Riconoscimenti - Informativa riconoscimenti CFU [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 127212 [type] => allegato [language] => it [created] => 1769682945 [changed] => 1771405077 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1771405077 [revision_uid] => 29556 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Informativa riconoscimenti CFU [format] => [safe_value] => Informativa riconoscimenti CFU ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 146323 [uid] => 29556 [filename] => Informativa riconoscimenti CFU agg.pdf [uri] => public://2026/Informativa riconoscimenti CFU agg.pdf [filemime] => application/pdf [filesize] => 309961 [status] => 1 [timestamp] => 1771405072 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2690 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => jessica.russo [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 516853 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) ) [2] => Array ( [nid] => 127213 [access] => 1 [node] => stdClass Object ( [vid] => 516854 [uid] => 29556 [title] => Riconoscimenti - Tabella convalida 24 CFU 2025-26 [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 127213 [type] => allegato [language] => it [created] => 1769683015 [changed] => 1769683015 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1769683015 [revision_uid] => 29556 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Tabella convalida 24 CFU 2025-26 [format] => [safe_value] => Tabella convalida 24 CFU 2025-26 ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 145763 [uid] => 29556 [filename] => Tabella convalida 24 CFU 2025_2026.pdf [uri] => public://2026/Tabella convalida 24 CFU 2025_2026.pdf [filemime] => application/pdf [filesize] => 129664 [status] => 1 [timestamp] => 1769683009 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2690 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => jessica.russo [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 516854 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) ) ) ) [field_outline_level] => Array ( [und] => Array ( [0] => Array ( [value] => h3 ) ) ) [field_titolo_frontend] => Array ( [und] => Array ( [0] => Array ( [value] => Riconoscimenti [format] => [safe_value] => Riconoscimenti ) ) ) [name] => jessica.russo [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 516855 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [nid] => 127526 [access] => 1 [node] => stdClass Object ( [vid] => 518122 [uid] => 32 [title] => Insegnamenti riconoscibili - Riconoscimenti - Informativa riconoscimenti CFU [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 127526 [type] => allegato [language] => it [created] => 1771228011 [changed] => 1771228011 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1771228011 [revision_uid] => 32 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Insegnamenti riconoscibili [format] => [safe_value] => Insegnamenti riconoscibili ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 146201 [uid] => 32 [filename] => Insegnamenti riconoscibili 2025_2026.pdf [uri] => public://2026/Insegnamenti riconoscibili 2025_2026.pdf [filemime] => application/pdf [filesize] => 313645 [status] => 1 [timestamp] => 1771228005 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2690 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => stefano.zampieri [picture] => 0 [data] => a:2:{s:13:"form_build_id";s:48:"form-WsCySmos4vAVlyFhG6gU5T7knfAyqco8LxlocSU_yIA";s:14:"wysiwyg_status";a:1:{i:1;i:1;}} [num_revisions] => 1 [current_revision_id] => 518122 [is_current] => 1 [is_pending] => [revision_moderation] => ) ) [1] => Array ( [nid] => 127212 [access] => 1 [node] => stdClass Object ( [vid] => 516853 [uid] => 29556 [title] => Riconoscimenti - Informativa riconoscimenti CFU [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 127212 [type] => allegato [language] => it [created] => 1769682945 [changed] => 1771405077 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1771405077 [revision_uid] => 29556 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Informativa riconoscimenti CFU [format] => [safe_value] => Informativa riconoscimenti CFU ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 146323 [uid] => 29556 [filename] => Informativa riconoscimenti CFU agg.pdf [uri] => public://2026/Informativa riconoscimenti CFU agg.pdf [filemime] => application/pdf [filesize] => 309961 [status] => 1 [timestamp] => 1771405072 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2690 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => jessica.russo [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 516853 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) ) [2] => Array ( [nid] => 127213 [access] => 1 [node] => stdClass Object ( [vid] => 516854 [uid] => 29556 [title] => Riconoscimenti - Tabella convalida 24 CFU 2025-26 [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 127213 [type] => allegato [language] => it [created] => 1769683015 [changed] => 1769683015 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1769683015 [revision_uid] => 29556 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Tabella convalida 24 CFU 2025-26 [format] => [safe_value] => Tabella convalida 24 CFU 2025-26 ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 145763 [uid] => 29556 [filename] => Tabella convalida 24 CFU 2025_2026.pdf [uri] => public://2026/Tabella convalida 24 CFU 2025_2026.pdf [filemime] => application/pdf [filesize] => 129664 [status] => 1 [timestamp] => 1769683009 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2690 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => jessica.russo [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 516854 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) ) ) [#formatter] => node_reference_default [0] => Array ( [#type] => link [#title] => Insegnamenti riconoscibili - Riconoscimenti - Informativa riconoscimenti CFU [#href] => node/127526 [#options] => Array ( [entity_type] => node [entity] => stdClass Object ( [vid] => 518122 [uid] => 32 [title] => Insegnamenti riconoscibili - Riconoscimenti - Informativa riconoscimenti CFU [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 127526 [type] => allegato [language] => it [created] => 1771228011 [changed] => 1771228011 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1771228011 [revision_uid] => 32 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Insegnamenti riconoscibili [format] => [safe_value] => Insegnamenti riconoscibili ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 146201 [uid] => 32 [filename] => Insegnamenti riconoscibili 2025_2026.pdf [uri] => public://2026/Insegnamenti riconoscibili 2025_2026.pdf [filemime] => application/pdf [filesize] => 313645 [status] => 1 [timestamp] => 1771228005 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2690 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => stefano.zampieri [picture] => 0 [data] => a:2:{s:13:"form_build_id";s:48:"form-WsCySmos4vAVlyFhG6gU5T7knfAyqco8LxlocSU_yIA";s:14:"wysiwyg_status";a:1:{i:1;i:1;}} [num_revisions] => 1 [current_revision_id] => 518122 [is_current] => 1 [is_pending] => [revision_moderation] => ) ) ) [1] => Array ( [#type] => link [#title] => Riconoscimenti - Informativa riconoscimenti CFU [#href] => node/127212 [#options] => Array ( [entity_type] => node [entity] => stdClass Object ( [vid] => 516853 [uid] => 29556 [title] => Riconoscimenti - Informativa riconoscimenti CFU [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 127212 [type] => allegato [language] => it [created] => 1769682945 [changed] => 1771405077 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1771405077 [revision_uid] => 29556 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Informativa riconoscimenti CFU [format] => [safe_value] => Informativa riconoscimenti CFU ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 146323 [uid] => 29556 [filename] => Informativa riconoscimenti CFU agg.pdf [uri] => public://2026/Informativa riconoscimenti CFU agg.pdf [filemime] => application/pdf [filesize] => 309961 [status] => 1 [timestamp] => 1771405072 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2690 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => jessica.russo [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 516853 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) ) ) [2] => Array ( [#type] => link [#title] => Riconoscimenti - Tabella convalida 24 CFU 2025-26 [#href] => node/127213 [#options] => Array ( [entity_type] => node [entity] => stdClass Object ( [vid] => 516854 [uid] => 29556 [title] => Riconoscimenti - Tabella convalida 24 CFU 2025-26 [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 127213 [type] => allegato [language] => it [created] => 1769683015 [changed] => 1769683015 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1769683015 [revision_uid] => 29556 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Tabella convalida 24 CFU 2025-26 [format] => [safe_value] => Tabella convalida 24 CFU 2025-26 ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 145763 [uid] => 29556 [filename] => Tabella convalida 24 CFU 2025_2026.pdf [uri] => public://2026/Tabella convalida 24 CFU 2025_2026.pdf [filemime] => application/pdf [filesize] => 129664 [status] => 1 [timestamp] => 1769683009 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2690 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => jessica.russo [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 516854 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) ) ) ) [field_accordion_state] => Array ( [#theme] => field [#weight] => -1 [#title] => Aperto/Chiuso [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_accordion_state [#field_type] => list_text [#field_translatable] => 0 [#entity_type] => node [#bundle] => elemento_accordion [#object] => stdClass Object ( [vid] => 516855 [uid] => 29556 [title] => Riconoscimenti - Percorsi abilitanti di formazione iniziale degli insegnanti [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 127214 [type] => elemento_accordion [language] => it [created] => 1769683023 [changed] => 1774517613 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1774517613 [revision_uid] => 29556 [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_accordion_state] => Array ( [und] => Array ( [0] => Array ( [value] => chiuso ) ) ) [field_allegato_element] => Array ( [und] => Array ( [0] => Array ( [nid] => 127526 [access] => 1 [node] => stdClass Object ( [vid] => 518122 [uid] => 32 [title] => Insegnamenti riconoscibili - Riconoscimenti - Informativa riconoscimenti CFU [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 127526 [type] => allegato [language] => it [created] => 1771228011 [changed] => 1771228011 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1771228011 [revision_uid] => 32 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Insegnamenti riconoscibili [format] => [safe_value] => Insegnamenti riconoscibili ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 146201 [uid] => 32 [filename] => Insegnamenti riconoscibili 2025_2026.pdf [uri] => public://2026/Insegnamenti riconoscibili 2025_2026.pdf [filemime] => application/pdf [filesize] => 313645 [status] => 1 [timestamp] => 1771228005 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2690 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => stefano.zampieri [picture] => 0 [data] => a:2:{s:13:"form_build_id";s:48:"form-WsCySmos4vAVlyFhG6gU5T7knfAyqco8LxlocSU_yIA";s:14:"wysiwyg_status";a:1:{i:1;i:1;}} [num_revisions] => 1 [current_revision_id] => 518122 [is_current] => 1 [is_pending] => [revision_moderation] => ) ) [1] => Array ( [nid] => 127212 [access] => 1 [node] => stdClass Object ( [vid] => 516853 [uid] => 29556 [title] => Riconoscimenti - Informativa riconoscimenti CFU [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 127212 [type] => allegato [language] => it [created] => 1769682945 [changed] => 1771405077 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1771405077 [revision_uid] => 29556 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Informativa riconoscimenti CFU [format] => [safe_value] => Informativa riconoscimenti CFU ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 146323 [uid] => 29556 [filename] => Informativa riconoscimenti CFU agg.pdf [uri] => public://2026/Informativa riconoscimenti CFU agg.pdf [filemime] => application/pdf [filesize] => 309961 [status] => 1 [timestamp] => 1771405072 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2690 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => jessica.russo [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 516853 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) ) [2] => Array ( [nid] => 127213 [access] => 1 [node] => stdClass Object ( [vid] => 516854 [uid] => 29556 [title] => Riconoscimenti - Tabella convalida 24 CFU 2025-26 [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 127213 [type] => allegato [language] => it [created] => 1769683015 [changed] => 1769683015 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1769683015 [revision_uid] => 29556 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Tabella convalida 24 CFU 2025-26 [format] => [safe_value] => Tabella convalida 24 CFU 2025-26 ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 145763 [uid] => 29556 [filename] => Tabella convalida 24 CFU 2025_2026.pdf [uri] => public://2026/Tabella convalida 24 CFU 2025_2026.pdf [filemime] => application/pdf [filesize] => 129664 [status] => 1 [timestamp] => 1769683009 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2690 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => jessica.russo [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 516854 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) ) ) ) [field_outline_level] => Array ( [und] => Array ( [0] => Array ( [value] => h3 ) ) ) [field_titolo_frontend] => Array ( [und] => Array ( [0] => Array ( [value] => Riconoscimenti [format] => [safe_value] => Riconoscimenti ) ) ) [name] => jessica.russo [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 516855 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => chiuso ) ) [#formatter] => text_default [0] => Array ( [#markup] => chiuso ) ) [links] => Array ( [#theme] => links__node [#pre_render] => Array ( [0] => drupal_pre_render_links ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) [node] => Array ( [#theme] => links__node__node [#links] => Array ( [node-readmore] => Array ( [title] => Read more about Riconoscimenti - Percorsi abilitanti di formazione iniziale degli insegnanti [href] => node/127214 [html] => 1 [attributes] => Array ( [rel] => tag [title] => Riconoscimenti - Percorsi abilitanti di formazione iniziale degli insegnanti ) ) ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) ) ) [field_outline_level] => Array ( [#theme] => field [#weight] => 31 [#title] => Livello outline [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_outline_level [#field_type] => list_text [#field_translatable] => 0 [#entity_type] => node [#bundle] => elemento_accordion [#object] => stdClass Object ( [vid] => 516855 [uid] => 29556 [title] => Riconoscimenti - Percorsi abilitanti di formazione iniziale degli insegnanti [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 127214 [type] => elemento_accordion [language] => it [created] => 1769683023 [changed] => 1774517613 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1774517613 [revision_uid] => 29556 [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_accordion_state] => Array ( [und] => Array ( [0] => Array ( [value] => chiuso ) ) ) [field_allegato_element] => Array ( [und] => Array ( [0] => Array ( [nid] => 127526 [access] => 1 [node] => stdClass Object ( [vid] => 518122 [uid] => 32 [title] => Insegnamenti riconoscibili - Riconoscimenti - Informativa riconoscimenti CFU [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 127526 [type] => allegato [language] => it [created] => 1771228011 [changed] => 1771228011 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1771228011 [revision_uid] => 32 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Insegnamenti riconoscibili [format] => [safe_value] => Insegnamenti riconoscibili ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 146201 [uid] => 32 [filename] => Insegnamenti riconoscibili 2025_2026.pdf [uri] => public://2026/Insegnamenti riconoscibili 2025_2026.pdf [filemime] => application/pdf [filesize] => 313645 [status] => 1 [timestamp] => 1771228005 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2690 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => stefano.zampieri [picture] => 0 [data] => a:2:{s:13:"form_build_id";s:48:"form-WsCySmos4vAVlyFhG6gU5T7knfAyqco8LxlocSU_yIA";s:14:"wysiwyg_status";a:1:{i:1;i:1;}} [num_revisions] => 1 [current_revision_id] => 518122 [is_current] => 1 [is_pending] => [revision_moderation] => ) ) [1] => Array ( [nid] => 127212 [access] => 1 [node] => stdClass Object ( [vid] => 516853 [uid] => 29556 [title] => Riconoscimenti - Informativa riconoscimenti CFU [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 127212 [type] => allegato [language] => it [created] => 1769682945 [changed] => 1771405077 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1771405077 [revision_uid] => 29556 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Informativa riconoscimenti CFU [format] => [safe_value] => Informativa riconoscimenti CFU ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 146323 [uid] => 29556 [filename] => Informativa riconoscimenti CFU agg.pdf [uri] => public://2026/Informativa riconoscimenti CFU agg.pdf [filemime] => application/pdf [filesize] => 309961 [status] => 1 [timestamp] => 1771405072 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2690 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => jessica.russo [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 516853 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) ) [2] => Array ( [nid] => 127213 [access] => 1 [node] => stdClass Object ( [vid] => 516854 [uid] => 29556 [title] => Riconoscimenti - Tabella convalida 24 CFU 2025-26 [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 127213 [type] => allegato [language] => it [created] => 1769683015 [changed] => 1769683015 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1769683015 [revision_uid] => 29556 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Tabella convalida 24 CFU 2025-26 [format] => [safe_value] => Tabella convalida 24 CFU 2025-26 ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 145763 [uid] => 29556 [filename] => Tabella convalida 24 CFU 2025_2026.pdf [uri] => public://2026/Tabella convalida 24 CFU 2025_2026.pdf [filemime] => application/pdf [filesize] => 129664 [status] => 1 [timestamp] => 1769683009 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2690 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => jessica.russo [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 516854 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) ) ) ) [field_outline_level] => Array ( [und] => Array ( [0] => Array ( [value] => h3 ) ) ) [field_titolo_frontend] => Array ( [und] => Array ( [0] => Array ( [value] => Riconoscimenti [format] => [safe_value] => Riconoscimenti ) ) ) [name] => jessica.russo [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 516855 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => h3 ) ) [#formatter] => text_default [0] => Array ( [#markup] => h3 ) ) )

Riconoscimenti - Tabella convalida 24 CFU 2025-26

Array ( [field_titolo_frontend_all] => Array ( [#theme] => field [#weight] => -4 [#title] => Titolo frontend [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_titolo_frontend_all [#field_type] => text_long [#field_translatable] => 0 [#entity_type] => node [#bundle] => allegato [#object] => stdClass Object ( [vid] => 516854 [uid] => 29556 [title] => Riconoscimenti - Tabella convalida 24 CFU 2025-26 [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 127213 [type] => allegato [language] => it [created] => 1769683015 [changed] => 1769683015 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1769683015 [revision_uid] => 29556 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Tabella convalida 24 CFU 2025-26 [format] => [safe_value] => Tabella convalida 24 CFU 2025-26 ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 145763 [uid] => 29556 [filename] => Tabella convalida 24 CFU 2025_2026.pdf [uri] => public://2026/Tabella convalida 24 CFU 2025_2026.pdf [filemime] => application/pdf [filesize] => 129664 [status] => 1 [timestamp] => 1769683009 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2690 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => jessica.russo [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 516854 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => Tabella convalida 24 CFU 2025-26 [format] => [safe_value] => Tabella convalida 24 CFU 2025-26 ) ) [#formatter] => text_default [0] => Array ( [#markup] => Tabella convalida 24 CFU 2025-26 ) ) [field_allegato_file] => Array ( [#theme] => field [#weight] => -3 [#title] => File [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_allegato_file [#field_type] => file [#field_translatable] => 0 [#entity_type] => node [#bundle] => allegato [#object] => stdClass Object ( [vid] => 516854 [uid] => 29556 [title] => Riconoscimenti - Tabella convalida 24 CFU 2025-26 [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 127213 [type] => allegato [language] => it [created] => 1769683015 [changed] => 1769683015 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1769683015 [revision_uid] => 29556 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Tabella convalida 24 CFU 2025-26 [format] => [safe_value] => Tabella convalida 24 CFU 2025-26 ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 145763 [uid] => 29556 [filename] => Tabella convalida 24 CFU 2025_2026.pdf [uri] => public://2026/Tabella convalida 24 CFU 2025_2026.pdf [filemime] => application/pdf [filesize] => 129664 [status] => 1 [timestamp] => 1769683009 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2690 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => jessica.russo [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 516854 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [fid] => 145763 [uid] => 29556 [filename] => Tabella convalida 24 CFU 2025_2026.pdf [uri] => public://2026/Tabella convalida 24 CFU 2025_2026.pdf [filemime] => application/pdf [filesize] => 129664 [status] => 1 [timestamp] => 1769683009 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2690 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) [#formatter] => file_default [0] => Array ( [#theme] => file_link [#file] => stdClass Object ( [fid] => 145763 [uid] => 29556 [filename] => Tabella convalida 24 CFU 2025_2026.pdf [uri] => public://2026/Tabella convalida 24 CFU 2025_2026.pdf [filemime] => application/pdf [filesize] => 129664 [status] => 1 [timestamp] => 1769683009 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2690 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [links] => Array ( [#theme] => links__node [#pre_render] => Array ( [0] => drupal_pre_render_links ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) [node] => Array ( [#theme] => links__node__node [#links] => Array ( [node-readmore] => Array ( [title] => Read more about Riconoscimenti - Tabella convalida 24 CFU 2025-26 [href] => node/127213 [html] => 1 [attributes] => Array ( [rel] => tag [title] => Riconoscimenti - Tabella convalida 24 CFU 2025-26 ) ) ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) ) ) )

Riconoscimenti - Informativa riconoscimenti CFU

Array ( [field_titolo_frontend_all] => Array ( [#theme] => field [#weight] => -4 [#title] => Titolo frontend [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_titolo_frontend_all [#field_type] => text_long [#field_translatable] => 0 [#entity_type] => node [#bundle] => allegato [#object] => stdClass Object ( [vid] => 516853 [uid] => 29556 [title] => Riconoscimenti - Informativa riconoscimenti CFU [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 127212 [type] => allegato [language] => it [created] => 1769682945 [changed] => 1771405077 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1771405077 [revision_uid] => 29556 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Informativa riconoscimenti CFU [format] => [safe_value] => Informativa riconoscimenti CFU ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 146323 [uid] => 29556 [filename] => Informativa riconoscimenti CFU agg.pdf [uri] => public://2026/Informativa riconoscimenti CFU agg.pdf [filemime] => application/pdf [filesize] => 309961 [status] => 1 [timestamp] => 1771405072 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2690 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => jessica.russo [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 516853 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => Informativa riconoscimenti CFU [format] => [safe_value] => Informativa riconoscimenti CFU ) ) [#formatter] => text_default [0] => Array ( [#markup] => Informativa riconoscimenti CFU ) ) [field_allegato_file] => Array ( [#theme] => field [#weight] => -3 [#title] => File [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_allegato_file [#field_type] => file [#field_translatable] => 0 [#entity_type] => node [#bundle] => allegato [#object] => stdClass Object ( [vid] => 516853 [uid] => 29556 [title] => Riconoscimenti - Informativa riconoscimenti CFU [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 127212 [type] => allegato [language] => it [created] => 1769682945 [changed] => 1771405077 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1771405077 [revision_uid] => 29556 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Informativa riconoscimenti CFU [format] => [safe_value] => Informativa riconoscimenti CFU ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 146323 [uid] => 29556 [filename] => Informativa riconoscimenti CFU agg.pdf [uri] => public://2026/Informativa riconoscimenti CFU agg.pdf [filemime] => application/pdf [filesize] => 309961 [status] => 1 [timestamp] => 1771405072 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2690 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => jessica.russo [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 516853 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [fid] => 146323 [uid] => 29556 [filename] => Informativa riconoscimenti CFU agg.pdf [uri] => public://2026/Informativa riconoscimenti CFU agg.pdf [filemime] => application/pdf [filesize] => 309961 [status] => 1 [timestamp] => 1771405072 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2690 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) [#formatter] => file_default [0] => Array ( [#theme] => file_link [#file] => stdClass Object ( [fid] => 146323 [uid] => 29556 [filename] => Informativa riconoscimenti CFU agg.pdf [uri] => public://2026/Informativa riconoscimenti CFU agg.pdf [filemime] => application/pdf [filesize] => 309961 [status] => 1 [timestamp] => 1771405072 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2690 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [links] => Array ( [#theme] => links__node [#pre_render] => Array ( [0] => drupal_pre_render_links ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) [node] => Array ( [#theme] => links__node__node [#links] => Array ( [node-readmore] => Array ( [title] => Read more about Riconoscimenti - Informativa riconoscimenti CFU [href] => node/127212 [html] => 1 [attributes] => Array ( [rel] => tag [title] => Riconoscimenti - Informativa riconoscimenti CFU ) ) ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) ) ) )

Low-dose Psilocybin: metabolic benefits without psychedelic effects

Array ( [body] => Array ( [#theme] => field [#weight] => 0 [#title] => Body [#access] => 1 [#label_display] => hidden [#view_mode] => teaser [#language] => und [#field_name] => body [#field_type] => text_with_summary [#field_translatable] => 0 [#entity_type] => node [#bundle] => box_lancio_news [#object] => stdClass Object ( [vid] => 521821 [uid] => 26499 [title] => Low-dose Psilocybin: metabolic benefits without psychedelic effects [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 127211 [type] => box_lancio_news [language] => it [created] => 1769681690 [changed] => 1774270708 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1774270708 [revision_uid] => 26499 [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

A preclinical study, published in the journal "Pharmacological Research" and led by the Universities of Padua and Milan, shows that chronic administration of very low, non-psychedelic doses of psilocybin produces metabolic benefits in models of obesity, type 2 diabetes, and metabolic dysfunction-associated fatty liver disease (MASLD).

In a diet-induced metabolic disease model, long-term treatment with psilocybin resulted in reduced weight gain, improved insulin sensitivity, normalised blood glucose levels, and regression of fatty liver, without reducing food intake and without side effects on the central nervous system.

Through molecular analysis, the study demonstrated an almost complete normalisation of liver metabolism, reducing "toxic" fats and reactivating mechanisms that allow insulin to function properly; these changes also reflect a visible improvement in liver structure and key metabolic indicators.

"These data challenge the idea that the therapeutic potential of psilocybin is necessarily linked to the psychedelic experience," observes Sara De Martin, corresponding author of the research and professor at the Department of Pharmaceutical Sciences at the University of Padua. "At chronic low doses, psilocybin acts as a peripheral modulator of metabolism, particularly at the liver level, through a distinct serotonergic pathway."

"These studies, conducted in an experimental mouse model, suggest that psilocybin could represent a new treatment for MASLD, type 2 diabetes, and obesity in humans," adds Franco Folli, corresponding author and professor at the Department of Health Sciences at the University of Milan.

The study was conducted as part of an international and multi-institutional collaboration, led by the University of Padua and the University of Milan, with the Institute of Oncology Research (IOR) in Bellinzona, the Socio-Sanitary Territorial Company (ASST) of the Seven Lakes in Varese, and the University of Insubria, supported by MGGM Therapeutics (New York) and Neuroarbor Therapeutics (Delaware), involving research centres in Italy, Switzerland, Germany, and the United States.

[summary] => [format] => 2 [safe_value] =>

A preclinical study, published in the journal "Pharmacological Research" and led by the Universities of Padua and Milan, shows that chronic administration of very low, non-psychedelic doses of psilocybin produces metabolic benefits in models of obesity, type 2 diabetes, and metabolic dysfunction-associated fatty liver disease (MASLD).

In a diet-induced metabolic disease model, long-term treatment with psilocybin resulted in reduced weight gain, improved insulin sensitivity, normalised blood glucose levels, and regression of fatty liver, without reducing food intake and without side effects on the central nervous system.

Through molecular analysis, the study demonstrated an almost complete normalisation of liver metabolism, reducing "toxic" fats and reactivating mechanisms that allow insulin to function properly; these changes also reflect a visible improvement in liver structure and key metabolic indicators.

"These data challenge the idea that the therapeutic potential of psilocybin is necessarily linked to the psychedelic experience," observes Sara De Martin, corresponding author of the research and professor at the Department of Pharmaceutical Sciences at the University of Padua. "At chronic low doses, psilocybin acts as a peripheral modulator of metabolism, particularly at the liver level, through a distinct serotonergic pathway."

"These studies, conducted in an experimental mouse model, suggest that psilocybin could represent a new treatment for MASLD, type 2 diabetes, and obesity in humans," adds Franco Folli, corresponding author and professor at the Department of Health Sciences at the University of Milan.

The study was conducted as part of an international and multi-institutional collaboration, led by the University of Padua and the University of Milan, with the Institute of Oncology Research (IOR) in Bellinzona, the Socio-Sanitary Territorial Company (ASST) of the Seven Lakes in Varese, and the University of Insubria, supported by MGGM Therapeutics (New York) and Neuroarbor Therapeutics (Delaware), involving research centres in Italy, Switzerland, Germany, and the United States.

[safe_summary] => ) ) ) [field_date_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [value] => 2026-01-29T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_etichetta_box_lancio_news] => Array ( ) [field_img_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [fid] => 145761 [uid] => 26499 [filename] => psico.jpg [uri] => public://psico.jpg [filemime] => image/jpeg [filesize] => 240810 [status] => 1 [timestamp] => 1769681426 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 630 [width] => 1200 ) [height] => 630 [width] => 1200 [alt] => psychedelic image [title] => ) ) ) [field_link_alla_news] => Array ( ) [field_link_esterno_news] => Array ( ) [field_pagina_associata] => Array ( ) [field_link_etichetta] => Array ( ) [field_abstract_news] => Array ( [und] => Array ( [0] => Array ( [value] => A study coordinated by the Universities of Padua and Milan has demonstrated improvements in obesity, insulin resistance, and fatty liver disease with non-psychedelic doses [format] => [safe_value] => A study coordinated by the Universities of Padua and Milan has demonstrated improvements in obesity, insulin resistance, and fatty liver disease with non-psychedelic doses ) ) ) [field_allegato_news] => Array ( ) [field_categorie_news] => Array ( [und] => Array ( [0] => Array ( [tid] => 2296 ) ) ) [field_pub_date] => Array ( [und] => Array ( [0] => Array ( [value] => 2026-01-29T00:00:00 [value2] => 2027-01-29T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_layout_news] => Array ( [und] => Array ( [0] => Array ( [value] => single ) ) ) [field_testo_opzionale_news] => Array ( ) [field_url_en_page] => Array ( [und] => Array ( [0] => Array ( [value] => https://www.unipd.it/news/psilocibina-basse-dosi-benefici-metabolici-senza-effetti-psichedelici [format] => [safe_value] => https://www.unipd.it/news/psilocibina-basse-dosi-benefici-metabolici-senza-effetti-psichedelici ) ) ) [field_url_en_page_label] => Array ( [und] => Array ( [0] => Array ( [value] => Versione italiana [format] => [safe_value] => Versione italiana ) ) ) [path] => Array ( [pathauto] => 1 ) [name] => rossella.vezzosi [picture] => 0 [data] => b:0; [num_revisions] => 3 [current_revision_id] => 521821 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] =>

A preclinical study, published in the journal "Pharmacological Research" and led by the Universities of Padua and Milan, shows that chronic administration of very low, non-psychedelic doses of psilocybin produces metabolic benefits in models of obesity, type 2 diabetes, and metabolic dysfunction-associated fatty liver disease (MASLD).

In a diet-induced metabolic disease model, long-term treatment with psilocybin resulted in reduced weight gain, improved insulin sensitivity, normalised blood glucose levels, and regression of fatty liver, without reducing food intake and without side effects on the central nervous system.

Through molecular analysis, the study demonstrated an almost complete normalisation of liver metabolism, reducing "toxic" fats and reactivating mechanisms that allow insulin to function properly; these changes also reflect a visible improvement in liver structure and key metabolic indicators.

"These data challenge the idea that the therapeutic potential of psilocybin is necessarily linked to the psychedelic experience," observes Sara De Martin, corresponding author of the research and professor at the Department of Pharmaceutical Sciences at the University of Padua. "At chronic low doses, psilocybin acts as a peripheral modulator of metabolism, particularly at the liver level, through a distinct serotonergic pathway."

"These studies, conducted in an experimental mouse model, suggest that psilocybin could represent a new treatment for MASLD, type 2 diabetes, and obesity in humans," adds Franco Folli, corresponding author and professor at the Department of Health Sciences at the University of Milan.

The study was conducted as part of an international and multi-institutional collaboration, led by the University of Padua and the University of Milan, with the Institute of Oncology Research (IOR) in Bellinzona, the Socio-Sanitary Territorial Company (ASST) of the Seven Lakes in Varese, and the University of Insubria, supported by MGGM Therapeutics (New York) and Neuroarbor Therapeutics (Delaware), involving research centres in Italy, Switzerland, Germany, and the United States.

[summary] => [format] => 2 [safe_value] =>

A preclinical study, published in the journal "Pharmacological Research" and led by the Universities of Padua and Milan, shows that chronic administration of very low, non-psychedelic doses of psilocybin produces metabolic benefits in models of obesity, type 2 diabetes, and metabolic dysfunction-associated fatty liver disease (MASLD).

In a diet-induced metabolic disease model, long-term treatment with psilocybin resulted in reduced weight gain, improved insulin sensitivity, normalised blood glucose levels, and regression of fatty liver, without reducing food intake and without side effects on the central nervous system.

Through molecular analysis, the study demonstrated an almost complete normalisation of liver metabolism, reducing "toxic" fats and reactivating mechanisms that allow insulin to function properly; these changes also reflect a visible improvement in liver structure and key metabolic indicators.

"These data challenge the idea that the therapeutic potential of psilocybin is necessarily linked to the psychedelic experience," observes Sara De Martin, corresponding author of the research and professor at the Department of Pharmaceutical Sciences at the University of Padua. "At chronic low doses, psilocybin acts as a peripheral modulator of metabolism, particularly at the liver level, through a distinct serotonergic pathway."

"These studies, conducted in an experimental mouse model, suggest that psilocybin could represent a new treatment for MASLD, type 2 diabetes, and obesity in humans," adds Franco Folli, corresponding author and professor at the Department of Health Sciences at the University of Milan.

The study was conducted as part of an international and multi-institutional collaboration, led by the University of Padua and the University of Milan, with the Institute of Oncology Research (IOR) in Bellinzona, the Socio-Sanitary Territorial Company (ASST) of the Seven Lakes in Varese, and the University of Insubria, supported by MGGM Therapeutics (New York) and Neuroarbor Therapeutics (Delaware), involving research centres in Italy, Switzerland, Germany, and the United States.

[safe_summary] => ) ) [#formatter] => text_summary_or_trimmed [0] => Array ( [#markup] =>

A preclinical study, published in the journal "Pharmacological Research" and led by the Universities of Padua and Milan, shows that chronic administration of very low, non-psychedelic doses of psilocybin produces metabolic benefits in models of obesity, type 2 diabetes, and metabolic dysfunction-associated fatty liver disease (MASLD).

) ) [field_img_box_lancio_news] => Array ( [#theme] => field [#weight] => 0 [#title] => Immagine [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_img_box_lancio_news [#field_type] => image [#field_translatable] => 0 [#entity_type] => node [#bundle] => box_lancio_news [#object] => stdClass Object ( [vid] => 521821 [uid] => 26499 [title] => Low-dose Psilocybin: metabolic benefits without psychedelic effects [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 127211 [type] => box_lancio_news [language] => it [created] => 1769681690 [changed] => 1774270708 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1774270708 [revision_uid] => 26499 [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

A preclinical study, published in the journal "Pharmacological Research" and led by the Universities of Padua and Milan, shows that chronic administration of very low, non-psychedelic doses of psilocybin produces metabolic benefits in models of obesity, type 2 diabetes, and metabolic dysfunction-associated fatty liver disease (MASLD).

In a diet-induced metabolic disease model, long-term treatment with psilocybin resulted in reduced weight gain, improved insulin sensitivity, normalised blood glucose levels, and regression of fatty liver, without reducing food intake and without side effects on the central nervous system.

Through molecular analysis, the study demonstrated an almost complete normalisation of liver metabolism, reducing "toxic" fats and reactivating mechanisms that allow insulin to function properly; these changes also reflect a visible improvement in liver structure and key metabolic indicators.

"These data challenge the idea that the therapeutic potential of psilocybin is necessarily linked to the psychedelic experience," observes Sara De Martin, corresponding author of the research and professor at the Department of Pharmaceutical Sciences at the University of Padua. "At chronic low doses, psilocybin acts as a peripheral modulator of metabolism, particularly at the liver level, through a distinct serotonergic pathway."

"These studies, conducted in an experimental mouse model, suggest that psilocybin could represent a new treatment for MASLD, type 2 diabetes, and obesity in humans," adds Franco Folli, corresponding author and professor at the Department of Health Sciences at the University of Milan.

The study was conducted as part of an international and multi-institutional collaboration, led by the University of Padua and the University of Milan, with the Institute of Oncology Research (IOR) in Bellinzona, the Socio-Sanitary Territorial Company (ASST) of the Seven Lakes in Varese, and the University of Insubria, supported by MGGM Therapeutics (New York) and Neuroarbor Therapeutics (Delaware), involving research centres in Italy, Switzerland, Germany, and the United States.

[summary] => [format] => 2 [safe_value] =>

A preclinical study, published in the journal "Pharmacological Research" and led by the Universities of Padua and Milan, shows that chronic administration of very low, non-psychedelic doses of psilocybin produces metabolic benefits in models of obesity, type 2 diabetes, and metabolic dysfunction-associated fatty liver disease (MASLD).

In a diet-induced metabolic disease model, long-term treatment with psilocybin resulted in reduced weight gain, improved insulin sensitivity, normalised blood glucose levels, and regression of fatty liver, without reducing food intake and without side effects on the central nervous system.

Through molecular analysis, the study demonstrated an almost complete normalisation of liver metabolism, reducing "toxic" fats and reactivating mechanisms that allow insulin to function properly; these changes also reflect a visible improvement in liver structure and key metabolic indicators.

"These data challenge the idea that the therapeutic potential of psilocybin is necessarily linked to the psychedelic experience," observes Sara De Martin, corresponding author of the research and professor at the Department of Pharmaceutical Sciences at the University of Padua. "At chronic low doses, psilocybin acts as a peripheral modulator of metabolism, particularly at the liver level, through a distinct serotonergic pathway."

"These studies, conducted in an experimental mouse model, suggest that psilocybin could represent a new treatment for MASLD, type 2 diabetes, and obesity in humans," adds Franco Folli, corresponding author and professor at the Department of Health Sciences at the University of Milan.

The study was conducted as part of an international and multi-institutional collaboration, led by the University of Padua and the University of Milan, with the Institute of Oncology Research (IOR) in Bellinzona, the Socio-Sanitary Territorial Company (ASST) of the Seven Lakes in Varese, and the University of Insubria, supported by MGGM Therapeutics (New York) and Neuroarbor Therapeutics (Delaware), involving research centres in Italy, Switzerland, Germany, and the United States.

[safe_summary] => ) ) ) [field_date_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [value] => 2026-01-29T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_etichetta_box_lancio_news] => Array ( ) [field_img_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [fid] => 145761 [uid] => 26499 [filename] => psico.jpg [uri] => public://psico.jpg [filemime] => image/jpeg [filesize] => 240810 [status] => 1 [timestamp] => 1769681426 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 630 [width] => 1200 ) [height] => 630 [width] => 1200 [alt] => psychedelic image [title] => ) ) ) [field_link_alla_news] => Array ( ) [field_link_esterno_news] => Array ( ) [field_pagina_associata] => Array ( ) [field_link_etichetta] => Array ( ) [field_abstract_news] => Array ( [und] => Array ( [0] => Array ( [value] => A study coordinated by the Universities of Padua and Milan has demonstrated improvements in obesity, insulin resistance, and fatty liver disease with non-psychedelic doses [format] => [safe_value] => A study coordinated by the Universities of Padua and Milan has demonstrated improvements in obesity, insulin resistance, and fatty liver disease with non-psychedelic doses ) ) ) [field_allegato_news] => Array ( ) [field_categorie_news] => Array ( [und] => Array ( [0] => Array ( [tid] => 2296 ) ) ) [field_pub_date] => Array ( [und] => Array ( [0] => Array ( [value] => 2026-01-29T00:00:00 [value2] => 2027-01-29T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_layout_news] => Array ( [und] => Array ( [0] => Array ( [value] => single ) ) ) [field_testo_opzionale_news] => Array ( ) [field_url_en_page] => Array ( [und] => Array ( [0] => Array ( [value] => https://www.unipd.it/news/psilocibina-basse-dosi-benefici-metabolici-senza-effetti-psichedelici [format] => [safe_value] => https://www.unipd.it/news/psilocibina-basse-dosi-benefici-metabolici-senza-effetti-psichedelici ) ) ) [field_url_en_page_label] => Array ( [und] => Array ( [0] => Array ( [value] => Versione italiana [format] => [safe_value] => Versione italiana ) ) ) [path] => Array ( [pathauto] => 1 ) [name] => rossella.vezzosi [picture] => 0 [data] => b:0; [num_revisions] => 3 [current_revision_id] => 521821 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [fid] => 145761 [uid] => 26499 [filename] => psico.jpg [uri] => public://psico.jpg [filemime] => image/jpeg [filesize] => 240810 [status] => 1 [timestamp] => 1769681426 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 630 [width] => 1200 ) [height] => 630 [width] => 1200 [alt] => psychedelic image [title] => ) ) [#formatter] => image [0] => Array ( [#theme] => image_formatter [#item] => Array ( [fid] => 145761 [uid] => 26499 [filename] => psico.jpg [uri] => public://psico.jpg [filemime] => image/jpeg [filesize] => 240810 [status] => 1 [timestamp] => 1769681426 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 630 [width] => 1200 ) [height] => 630 [width] => 1200 [alt] => psychedelic image [title] => ) [#image_style] => [#path] => ) ) [field_abstract_news] => Array ( [#theme] => field [#weight] => 0 [#title] => Abstract [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_abstract_news [#field_type] => text_long [#field_translatable] => 0 [#entity_type] => node [#bundle] => box_lancio_news [#object] => stdClass Object ( [vid] => 521821 [uid] => 26499 [title] => Low-dose Psilocybin: metabolic benefits without psychedelic effects [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 127211 [type] => box_lancio_news [language] => it [created] => 1769681690 [changed] => 1774270708 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1774270708 [revision_uid] => 26499 [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

A preclinical study, published in the journal "Pharmacological Research" and led by the Universities of Padua and Milan, shows that chronic administration of very low, non-psychedelic doses of psilocybin produces metabolic benefits in models of obesity, type 2 diabetes, and metabolic dysfunction-associated fatty liver disease (MASLD).

In a diet-induced metabolic disease model, long-term treatment with psilocybin resulted in reduced weight gain, improved insulin sensitivity, normalised blood glucose levels, and regression of fatty liver, without reducing food intake and without side effects on the central nervous system.

Through molecular analysis, the study demonstrated an almost complete normalisation of liver metabolism, reducing "toxic" fats and reactivating mechanisms that allow insulin to function properly; these changes also reflect a visible improvement in liver structure and key metabolic indicators.

"These data challenge the idea that the therapeutic potential of psilocybin is necessarily linked to the psychedelic experience," observes Sara De Martin, corresponding author of the research and professor at the Department of Pharmaceutical Sciences at the University of Padua. "At chronic low doses, psilocybin acts as a peripheral modulator of metabolism, particularly at the liver level, through a distinct serotonergic pathway."

"These studies, conducted in an experimental mouse model, suggest that psilocybin could represent a new treatment for MASLD, type 2 diabetes, and obesity in humans," adds Franco Folli, corresponding author and professor at the Department of Health Sciences at the University of Milan.

The study was conducted as part of an international and multi-institutional collaboration, led by the University of Padua and the University of Milan, with the Institute of Oncology Research (IOR) in Bellinzona, the Socio-Sanitary Territorial Company (ASST) of the Seven Lakes in Varese, and the University of Insubria, supported by MGGM Therapeutics (New York) and Neuroarbor Therapeutics (Delaware), involving research centres in Italy, Switzerland, Germany, and the United States.

[summary] => [format] => 2 [safe_value] =>

A preclinical study, published in the journal "Pharmacological Research" and led by the Universities of Padua and Milan, shows that chronic administration of very low, non-psychedelic doses of psilocybin produces metabolic benefits in models of obesity, type 2 diabetes, and metabolic dysfunction-associated fatty liver disease (MASLD).

In a diet-induced metabolic disease model, long-term treatment with psilocybin resulted in reduced weight gain, improved insulin sensitivity, normalised blood glucose levels, and regression of fatty liver, without reducing food intake and without side effects on the central nervous system.

Through molecular analysis, the study demonstrated an almost complete normalisation of liver metabolism, reducing "toxic" fats and reactivating mechanisms that allow insulin to function properly; these changes also reflect a visible improvement in liver structure and key metabolic indicators.

"These data challenge the idea that the therapeutic potential of psilocybin is necessarily linked to the psychedelic experience," observes Sara De Martin, corresponding author of the research and professor at the Department of Pharmaceutical Sciences at the University of Padua. "At chronic low doses, psilocybin acts as a peripheral modulator of metabolism, particularly at the liver level, through a distinct serotonergic pathway."

"These studies, conducted in an experimental mouse model, suggest that psilocybin could represent a new treatment for MASLD, type 2 diabetes, and obesity in humans," adds Franco Folli, corresponding author and professor at the Department of Health Sciences at the University of Milan.

The study was conducted as part of an international and multi-institutional collaboration, led by the University of Padua and the University of Milan, with the Institute of Oncology Research (IOR) in Bellinzona, the Socio-Sanitary Territorial Company (ASST) of the Seven Lakes in Varese, and the University of Insubria, supported by MGGM Therapeutics (New York) and Neuroarbor Therapeutics (Delaware), involving research centres in Italy, Switzerland, Germany, and the United States.

[safe_summary] => ) ) ) [field_date_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [value] => 2026-01-29T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_etichetta_box_lancio_news] => Array ( ) [field_img_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [fid] => 145761 [uid] => 26499 [filename] => psico.jpg [uri] => public://psico.jpg [filemime] => image/jpeg [filesize] => 240810 [status] => 1 [timestamp] => 1769681426 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 630 [width] => 1200 ) [height] => 630 [width] => 1200 [alt] => psychedelic image [title] => ) ) ) [field_link_alla_news] => Array ( ) [field_link_esterno_news] => Array ( ) [field_pagina_associata] => Array ( ) [field_link_etichetta] => Array ( ) [field_abstract_news] => Array ( [und] => Array ( [0] => Array ( [value] => A study coordinated by the Universities of Padua and Milan has demonstrated improvements in obesity, insulin resistance, and fatty liver disease with non-psychedelic doses [format] => [safe_value] => A study coordinated by the Universities of Padua and Milan has demonstrated improvements in obesity, insulin resistance, and fatty liver disease with non-psychedelic doses ) ) ) [field_allegato_news] => Array ( ) [field_categorie_news] => Array ( [und] => Array ( [0] => Array ( [tid] => 2296 ) ) ) [field_pub_date] => Array ( [und] => Array ( [0] => Array ( [value] => 2026-01-29T00:00:00 [value2] => 2027-01-29T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_layout_news] => Array ( [und] => Array ( [0] => Array ( [value] => single ) ) ) [field_testo_opzionale_news] => Array ( ) [field_url_en_page] => Array ( [und] => Array ( [0] => Array ( [value] => https://www.unipd.it/news/psilocibina-basse-dosi-benefici-metabolici-senza-effetti-psichedelici [format] => [safe_value] => https://www.unipd.it/news/psilocibina-basse-dosi-benefici-metabolici-senza-effetti-psichedelici ) ) ) [field_url_en_page_label] => Array ( [und] => Array ( [0] => Array ( [value] => Versione italiana [format] => [safe_value] => Versione italiana ) ) ) [path] => Array ( [pathauto] => 1 ) [name] => rossella.vezzosi [picture] => 0 [data] => b:0; [num_revisions] => 3 [current_revision_id] => 521821 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => A study coordinated by the Universities of Padua and Milan has demonstrated improvements in obesity, insulin resistance, and fatty liver disease with non-psychedelic doses [format] => [safe_value] => A study coordinated by the Universities of Padua and Milan has demonstrated improvements in obesity, insulin resistance, and fatty liver disease with non-psychedelic doses ) ) [#formatter] => text_default [0] => Array ( [#markup] => A study coordinated by the Universities of Padua and Milan has demonstrated improvements in obesity, insulin resistance, and fatty liver disease with non-psychedelic doses ) ) [links] => Array ( [#theme] => links__node [#pre_render] => Array ( [0] => drupal_pre_render_links ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) [node] => Array ( [#theme] => links__node__node [#links] => Array ( [node-readmore] => Array ( [title] => Read more about Low-dose Psilocybin: metabolic benefits without psychedelic effects [href] => node/127211 [html] => 1 [attributes] => Array ( [rel] => tag [title] => Low-dose Psilocybin: metabolic benefits without psychedelic effects ) ) ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) ) ) [field_date_box_lancio_news] => Array ( [#theme] => field [#weight] => 1 [#title] => Data [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_date_box_lancio_news [#field_type] => date [#field_translatable] => 0 [#entity_type] => node [#bundle] => box_lancio_news [#object] => stdClass Object ( [vid] => 521821 [uid] => 26499 [title] => Low-dose Psilocybin: metabolic benefits without psychedelic effects [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 127211 [type] => box_lancio_news [language] => it [created] => 1769681690 [changed] => 1774270708 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1774270708 [revision_uid] => 26499 [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

A preclinical study, published in the journal "Pharmacological Research" and led by the Universities of Padua and Milan, shows that chronic administration of very low, non-psychedelic doses of psilocybin produces metabolic benefits in models of obesity, type 2 diabetes, and metabolic dysfunction-associated fatty liver disease (MASLD).

In a diet-induced metabolic disease model, long-term treatment with psilocybin resulted in reduced weight gain, improved insulin sensitivity, normalised blood glucose levels, and regression of fatty liver, without reducing food intake and without side effects on the central nervous system.

Through molecular analysis, the study demonstrated an almost complete normalisation of liver metabolism, reducing "toxic" fats and reactivating mechanisms that allow insulin to function properly; these changes also reflect a visible improvement in liver structure and key metabolic indicators.

"These data challenge the idea that the therapeutic potential of psilocybin is necessarily linked to the psychedelic experience," observes Sara De Martin, corresponding author of the research and professor at the Department of Pharmaceutical Sciences at the University of Padua. "At chronic low doses, psilocybin acts as a peripheral modulator of metabolism, particularly at the liver level, through a distinct serotonergic pathway."

"These studies, conducted in an experimental mouse model, suggest that psilocybin could represent a new treatment for MASLD, type 2 diabetes, and obesity in humans," adds Franco Folli, corresponding author and professor at the Department of Health Sciences at the University of Milan.

The study was conducted as part of an international and multi-institutional collaboration, led by the University of Padua and the University of Milan, with the Institute of Oncology Research (IOR) in Bellinzona, the Socio-Sanitary Territorial Company (ASST) of the Seven Lakes in Varese, and the University of Insubria, supported by MGGM Therapeutics (New York) and Neuroarbor Therapeutics (Delaware), involving research centres in Italy, Switzerland, Germany, and the United States.

[summary] => [format] => 2 [safe_value] =>

A preclinical study, published in the journal "Pharmacological Research" and led by the Universities of Padua and Milan, shows that chronic administration of very low, non-psychedelic doses of psilocybin produces metabolic benefits in models of obesity, type 2 diabetes, and metabolic dysfunction-associated fatty liver disease (MASLD).

In a diet-induced metabolic disease model, long-term treatment with psilocybin resulted in reduced weight gain, improved insulin sensitivity, normalised blood glucose levels, and regression of fatty liver, without reducing food intake and without side effects on the central nervous system.

Through molecular analysis, the study demonstrated an almost complete normalisation of liver metabolism, reducing "toxic" fats and reactivating mechanisms that allow insulin to function properly; these changes also reflect a visible improvement in liver structure and key metabolic indicators.

"These data challenge the idea that the therapeutic potential of psilocybin is necessarily linked to the psychedelic experience," observes Sara De Martin, corresponding author of the research and professor at the Department of Pharmaceutical Sciences at the University of Padua. "At chronic low doses, psilocybin acts as a peripheral modulator of metabolism, particularly at the liver level, through a distinct serotonergic pathway."

"These studies, conducted in an experimental mouse model, suggest that psilocybin could represent a new treatment for MASLD, type 2 diabetes, and obesity in humans," adds Franco Folli, corresponding author and professor at the Department of Health Sciences at the University of Milan.

The study was conducted as part of an international and multi-institutional collaboration, led by the University of Padua and the University of Milan, with the Institute of Oncology Research (IOR) in Bellinzona, the Socio-Sanitary Territorial Company (ASST) of the Seven Lakes in Varese, and the University of Insubria, supported by MGGM Therapeutics (New York) and Neuroarbor Therapeutics (Delaware), involving research centres in Italy, Switzerland, Germany, and the United States.

[safe_summary] => ) ) ) [field_date_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [value] => 2026-01-29T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_etichetta_box_lancio_news] => Array ( ) [field_img_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [fid] => 145761 [uid] => 26499 [filename] => psico.jpg [uri] => public://psico.jpg [filemime] => image/jpeg [filesize] => 240810 [status] => 1 [timestamp] => 1769681426 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 630 [width] => 1200 ) [height] => 630 [width] => 1200 [alt] => psychedelic image [title] => ) ) ) [field_link_alla_news] => Array ( ) [field_link_esterno_news] => Array ( ) [field_pagina_associata] => Array ( ) [field_link_etichetta] => Array ( ) [field_abstract_news] => Array ( [und] => Array ( [0] => Array ( [value] => A study coordinated by the Universities of Padua and Milan has demonstrated improvements in obesity, insulin resistance, and fatty liver disease with non-psychedelic doses [format] => [safe_value] => A study coordinated by the Universities of Padua and Milan has demonstrated improvements in obesity, insulin resistance, and fatty liver disease with non-psychedelic doses ) ) ) [field_allegato_news] => Array ( ) [field_categorie_news] => Array ( [und] => Array ( [0] => Array ( [tid] => 2296 ) ) ) [field_pub_date] => Array ( [und] => Array ( [0] => Array ( [value] => 2026-01-29T00:00:00 [value2] => 2027-01-29T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_layout_news] => Array ( [und] => Array ( [0] => Array ( [value] => single ) ) ) [field_testo_opzionale_news] => Array ( ) [field_url_en_page] => Array ( [und] => Array ( [0] => Array ( [value] => https://www.unipd.it/news/psilocibina-basse-dosi-benefici-metabolici-senza-effetti-psichedelici [format] => [safe_value] => https://www.unipd.it/news/psilocibina-basse-dosi-benefici-metabolici-senza-effetti-psichedelici ) ) ) [field_url_en_page_label] => Array ( [und] => Array ( [0] => Array ( [value] => Versione italiana [format] => [safe_value] => Versione italiana ) ) ) [path] => Array ( [pathauto] => 1 ) [name] => rossella.vezzosi [picture] => 0 [data] => b:0; [num_revisions] => 3 [current_revision_id] => 521821 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => 2026-01-29T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) [#formatter] => date_default [0] => Array ( [#markup] => Gio, 29/01/2026 ) ) )

Psilocibina a basse dosi: benefici metabolici senza effetti psichedelici

Array ( [body] => Array ( [#theme] => field [#weight] => 0 [#title] => Body [#access] => 1 [#label_display] => hidden [#view_mode] => teaser [#language] => und [#field_name] => body [#field_type] => text_with_summary [#field_translatable] => 0 [#entity_type] => node [#bundle] => box_lancio_news [#object] => stdClass Object ( [vid] => 516846 [uid] => 26499 [title] => Psilocibina a basse dosi: benefici metabolici senza effetti psichedelici [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 127210 [type] => box_lancio_news [language] => it [created] => 1769681426 [changed] => 1769681760 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1769681760 [revision_uid] => 26499 [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

Uno studio preclinico, pubblicato sulla rivista «Pharmacological Research» e guidato dalle Università di Padova e Milano, mostra che la somministrazione cronica di dosi molto basse e non psichedeliche di psilocibina produce benefici metabolici in modelli di obesità, diabete di tipo 2 e steatosi epatica associata a disfunzione metabolica (MASLD).

In un modello di malattia metabolica indotta dalla dieta, il trattamento a lungo termine con psilocibina ha determinato una riduzione dell’aumento ponderale, un miglioramento della sensibilità insulinica, la normalizzazione della glicemia e una regressione della steatosi epatica, senza ridurre l’assunzione di cibo e senza effetti collaterali sul sistema nervoso centrale.

Attraverso analisi molecolari, lo studio ha mostrato una quasi completa normalizzazione del metabolismo epatico, riducendo i grassi “tossici” e riattivando i meccanismi che permettono all’insulina di funzionare correttamente; questi cambiamenti si riflettono anche in un miglioramento visibile della struttura del fegato e dei principali indicatori metabolici.

«Questi dati mettono in discussione l’idea che il potenziale terapeutico della psilocibina sia necessariamente legato all’esperienza psichedelica – osserva Sara De Martin, corresponding author della ricerca e docente al Dipartimento di Scienze del farmaco dell’Università di Padova –. A basse dosi croniche, la psilocibina agisce come modulatore periferico del metabolismo, in particolare a livello epatico, attraverso un pathway serotoninergico distinto».

«Questi studi, condotti in un modello sperimentale nel topo, suggeriscono che la psilocibina potrebbe rappresentare una nuova cura per MASLD, il diabete di tipo 2 e l’obesità nell’uomo» aggiunge Franco Folli, corresponding author e docente al Dipartimento di Scienze della salute dell’Università di Milano.

Lo studio è stato condotto nell’ambito di una collaborazione internazionale e multi-istituzionale, guidata dall’Università di Padova e dall’Università di Milano, con l’Institute of Oncology Research (IOR) di Bellinzona, l’Azienda Socio-Sanitaria Territoriale (ASST) dei Sette Laghi di Varese e l’Università dell’Insubria, supportata da MGGM Therapeutics (New York) e Neuroarbor Therapeutics (Delaware), coinvolgendo centri di ricerca in Italia, Svizzera, Germania e Stati Uniti.

[summary] => [format] => 2 [safe_value] =>

Uno studio preclinico, pubblicato sulla rivista «Pharmacological Research» e guidato dalle Università di Padova e Milano, mostra che la somministrazione cronica di dosi molto basse e non psichedeliche di psilocibina produce benefici metabolici in modelli di obesità, diabete di tipo 2 e steatosi epatica associata a disfunzione metabolica (MASLD).

In un modello di malattia metabolica indotta dalla dieta, il trattamento a lungo termine con psilocibina ha determinato una riduzione dell’aumento ponderale, un miglioramento della sensibilità insulinica, la normalizzazione della glicemia e una regressione della steatosi epatica, senza ridurre l’assunzione di cibo e senza effetti collaterali sul sistema nervoso centrale.

Attraverso analisi molecolari, lo studio ha mostrato una quasi completa normalizzazione del metabolismo epatico, riducendo i grassi “tossici” e riattivando i meccanismi che permettono all’insulina di funzionare correttamente; questi cambiamenti si riflettono anche in un miglioramento visibile della struttura del fegato e dei principali indicatori metabolici.

«Questi dati mettono in discussione l’idea che il potenziale terapeutico della psilocibina sia necessariamente legato all’esperienza psichedelica – osserva Sara De Martin, corresponding author della ricerca e docente al Dipartimento di Scienze del farmaco dell’Università di Padova –. A basse dosi croniche, la psilocibina agisce come modulatore periferico del metabolismo, in particolare a livello epatico, attraverso un pathway serotoninergico distinto».

«Questi studi, condotti in un modello sperimentale nel topo, suggeriscono che la psilocibina potrebbe rappresentare una nuova cura per MASLD, il diabete di tipo 2 e l’obesità nell’uomo» aggiunge Franco Folli, corresponding author e docente al Dipartimento di Scienze della salute dell’Università di Milano.

Lo studio è stato condotto nell’ambito di una collaborazione internazionale e multi-istituzionale, guidata dall’Università di Padova e dall’Università di Milano, con l’Institute of Oncology Research (IOR) di Bellinzona, l’Azienda Socio-Sanitaria Territoriale (ASST) dei Sette Laghi di Varese e l’Università dell’Insubria, supportata da MGGM Therapeutics (New York) e Neuroarbor Therapeutics (Delaware), coinvolgendo centri di ricerca in Italia, Svizzera, Germania e Stati Uniti.

[safe_summary] => ) ) ) [field_date_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [value] => 2026-01-29T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_etichetta_box_lancio_news] => Array ( ) [field_img_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [fid] => 145761 [uid] => 26499 [filename] => psico.jpg [uri] => public://psico.jpg [filemime] => image/jpeg [filesize] => 240810 [status] => 1 [timestamp] => 1769681426 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 630 [width] => 1200 ) [height] => 630 [width] => 1200 [alt] => immagine psicadelica [title] => ) ) ) [field_link_alla_news] => Array ( ) [field_link_esterno_news] => Array ( ) [field_pagina_associata] => Array ( ) [field_link_etichetta] => Array ( ) [field_abstract_news] => Array ( [und] => Array ( [0] => Array ( [value] => Uno studio coordinato dalle Università di Padova e Milano ha dimostrato miglioramenti di obesità, insulino-resistenza e steatosi epatica con dosi non psichedeliche [format] => [safe_value] => Uno studio coordinato dalle Università di Padova e Milano ha dimostrato miglioramenti di obesità, insulino-resistenza e steatosi epatica con dosi non psichedeliche ) ) ) [field_allegato_news] => Array ( ) [field_categorie_news] => Array ( [und] => Array ( [0] => Array ( [tid] => 2264 ) [1] => Array ( [tid] => 2266 ) [2] => Array ( [tid] => 2267 ) [3] => Array ( [tid] => 2462 ) ) ) [field_pub_date] => Array ( [und] => Array ( [0] => Array ( [value] => 2026-01-29T00:00:00 [value2] => 2027-01-29T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_layout_news] => Array ( [und] => Array ( [0] => Array ( [value] => single ) ) ) [field_testo_opzionale_news] => Array ( ) [field_url_en_page] => Array ( [und] => Array ( [0] => Array ( [value] => https://www.unipd.it/news/low-dose-psilocybin-metabolic-benefits-without-psychedelic-effects [format] => [safe_value] => https://www.unipd.it/news/low-dose-psilocybin-metabolic-benefits-without-psychedelic-effects ) ) ) [field_url_en_page_label] => Array ( [und] => Array ( [0] => Array ( [value] => English version [format] => [safe_value] => English version ) ) ) [path] => Array ( [pathauto] => 1 ) [name] => rossella.vezzosi [picture] => 0 [data] => b:0; [num_revisions] => 2 [current_revision_id] => 516846 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] =>

Uno studio preclinico, pubblicato sulla rivista «Pharmacological Research» e guidato dalle Università di Padova e Milano, mostra che la somministrazione cronica di dosi molto basse e non psichedeliche di psilocibina produce benefici metabolici in modelli di obesità, diabete di tipo 2 e steatosi epatica associata a disfunzione metabolica (MASLD).

In un modello di malattia metabolica indotta dalla dieta, il trattamento a lungo termine con psilocibina ha determinato una riduzione dell’aumento ponderale, un miglioramento della sensibilità insulinica, la normalizzazione della glicemia e una regressione della steatosi epatica, senza ridurre l’assunzione di cibo e senza effetti collaterali sul sistema nervoso centrale.

Attraverso analisi molecolari, lo studio ha mostrato una quasi completa normalizzazione del metabolismo epatico, riducendo i grassi “tossici” e riattivando i meccanismi che permettono all’insulina di funzionare correttamente; questi cambiamenti si riflettono anche in un miglioramento visibile della struttura del fegato e dei principali indicatori metabolici.

«Questi dati mettono in discussione l’idea che il potenziale terapeutico della psilocibina sia necessariamente legato all’esperienza psichedelica – osserva Sara De Martin, corresponding author della ricerca e docente al Dipartimento di Scienze del farmaco dell’Università di Padova –. A basse dosi croniche, la psilocibina agisce come modulatore periferico del metabolismo, in particolare a livello epatico, attraverso un pathway serotoninergico distinto».

«Questi studi, condotti in un modello sperimentale nel topo, suggeriscono che la psilocibina potrebbe rappresentare una nuova cura per MASLD, il diabete di tipo 2 e l’obesità nell’uomo» aggiunge Franco Folli, corresponding author e docente al Dipartimento di Scienze della salute dell’Università di Milano.

Lo studio è stato condotto nell’ambito di una collaborazione internazionale e multi-istituzionale, guidata dall’Università di Padova e dall’Università di Milano, con l’Institute of Oncology Research (IOR) di Bellinzona, l’Azienda Socio-Sanitaria Territoriale (ASST) dei Sette Laghi di Varese e l’Università dell’Insubria, supportata da MGGM Therapeutics (New York) e Neuroarbor Therapeutics (Delaware), coinvolgendo centri di ricerca in Italia, Svizzera, Germania e Stati Uniti.

[summary] => [format] => 2 [safe_value] =>

Uno studio preclinico, pubblicato sulla rivista «Pharmacological Research» e guidato dalle Università di Padova e Milano, mostra che la somministrazione cronica di dosi molto basse e non psichedeliche di psilocibina produce benefici metabolici in modelli di obesità, diabete di tipo 2 e steatosi epatica associata a disfunzione metabolica (MASLD).

In un modello di malattia metabolica indotta dalla dieta, il trattamento a lungo termine con psilocibina ha determinato una riduzione dell’aumento ponderale, un miglioramento della sensibilità insulinica, la normalizzazione della glicemia e una regressione della steatosi epatica, senza ridurre l’assunzione di cibo e senza effetti collaterali sul sistema nervoso centrale.

Attraverso analisi molecolari, lo studio ha mostrato una quasi completa normalizzazione del metabolismo epatico, riducendo i grassi “tossici” e riattivando i meccanismi che permettono all’insulina di funzionare correttamente; questi cambiamenti si riflettono anche in un miglioramento visibile della struttura del fegato e dei principali indicatori metabolici.

«Questi dati mettono in discussione l’idea che il potenziale terapeutico della psilocibina sia necessariamente legato all’esperienza psichedelica – osserva Sara De Martin, corresponding author della ricerca e docente al Dipartimento di Scienze del farmaco dell’Università di Padova –. A basse dosi croniche, la psilocibina agisce come modulatore periferico del metabolismo, in particolare a livello epatico, attraverso un pathway serotoninergico distinto».

«Questi studi, condotti in un modello sperimentale nel topo, suggeriscono che la psilocibina potrebbe rappresentare una nuova cura per MASLD, il diabete di tipo 2 e l’obesità nell’uomo» aggiunge Franco Folli, corresponding author e docente al Dipartimento di Scienze della salute dell’Università di Milano.

Lo studio è stato condotto nell’ambito di una collaborazione internazionale e multi-istituzionale, guidata dall’Università di Padova e dall’Università di Milano, con l’Institute of Oncology Research (IOR) di Bellinzona, l’Azienda Socio-Sanitaria Territoriale (ASST) dei Sette Laghi di Varese e l’Università dell’Insubria, supportata da MGGM Therapeutics (New York) e Neuroarbor Therapeutics (Delaware), coinvolgendo centri di ricerca in Italia, Svizzera, Germania e Stati Uniti.

[safe_summary] => ) ) [#formatter] => text_summary_or_trimmed [0] => Array ( [#markup] =>

Uno studio preclinico, pubblicato sulla rivista «Pharmacological Research» e guidato dalle Università di Padova e Milano, mostra che la somministrazione cronica di dosi molto basse e non psichedeliche di psilocibina produce benefici metabolici in modelli di obesità, diabete di tipo 2 e steatosi epatica associata a disfunzione metabolica (MASLD).

) ) [field_img_box_lancio_news] => Array ( [#theme] => field [#weight] => 0 [#title] => Immagine [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_img_box_lancio_news [#field_type] => image [#field_translatable] => 0 [#entity_type] => node [#bundle] => box_lancio_news [#object] => stdClass Object ( [vid] => 516846 [uid] => 26499 [title] => Psilocibina a basse dosi: benefici metabolici senza effetti psichedelici [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 127210 [type] => box_lancio_news [language] => it [created] => 1769681426 [changed] => 1769681760 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1769681760 [revision_uid] => 26499 [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

Uno studio preclinico, pubblicato sulla rivista «Pharmacological Research» e guidato dalle Università di Padova e Milano, mostra che la somministrazione cronica di dosi molto basse e non psichedeliche di psilocibina produce benefici metabolici in modelli di obesità, diabete di tipo 2 e steatosi epatica associata a disfunzione metabolica (MASLD).

In un modello di malattia metabolica indotta dalla dieta, il trattamento a lungo termine con psilocibina ha determinato una riduzione dell’aumento ponderale, un miglioramento della sensibilità insulinica, la normalizzazione della glicemia e una regressione della steatosi epatica, senza ridurre l’assunzione di cibo e senza effetti collaterali sul sistema nervoso centrale.

Attraverso analisi molecolari, lo studio ha mostrato una quasi completa normalizzazione del metabolismo epatico, riducendo i grassi “tossici” e riattivando i meccanismi che permettono all’insulina di funzionare correttamente; questi cambiamenti si riflettono anche in un miglioramento visibile della struttura del fegato e dei principali indicatori metabolici.

«Questi dati mettono in discussione l’idea che il potenziale terapeutico della psilocibina sia necessariamente legato all’esperienza psichedelica – osserva Sara De Martin, corresponding author della ricerca e docente al Dipartimento di Scienze del farmaco dell’Università di Padova –. A basse dosi croniche, la psilocibina agisce come modulatore periferico del metabolismo, in particolare a livello epatico, attraverso un pathway serotoninergico distinto».

«Questi studi, condotti in un modello sperimentale nel topo, suggeriscono che la psilocibina potrebbe rappresentare una nuova cura per MASLD, il diabete di tipo 2 e l’obesità nell’uomo» aggiunge Franco Folli, corresponding author e docente al Dipartimento di Scienze della salute dell’Università di Milano.

Lo studio è stato condotto nell’ambito di una collaborazione internazionale e multi-istituzionale, guidata dall’Università di Padova e dall’Università di Milano, con l’Institute of Oncology Research (IOR) di Bellinzona, l’Azienda Socio-Sanitaria Territoriale (ASST) dei Sette Laghi di Varese e l’Università dell’Insubria, supportata da MGGM Therapeutics (New York) e Neuroarbor Therapeutics (Delaware), coinvolgendo centri di ricerca in Italia, Svizzera, Germania e Stati Uniti.

[summary] => [format] => 2 [safe_value] =>

Uno studio preclinico, pubblicato sulla rivista «Pharmacological Research» e guidato dalle Università di Padova e Milano, mostra che la somministrazione cronica di dosi molto basse e non psichedeliche di psilocibina produce benefici metabolici in modelli di obesità, diabete di tipo 2 e steatosi epatica associata a disfunzione metabolica (MASLD).

In un modello di malattia metabolica indotta dalla dieta, il trattamento a lungo termine con psilocibina ha determinato una riduzione dell’aumento ponderale, un miglioramento della sensibilità insulinica, la normalizzazione della glicemia e una regressione della steatosi epatica, senza ridurre l’assunzione di cibo e senza effetti collaterali sul sistema nervoso centrale.

Attraverso analisi molecolari, lo studio ha mostrato una quasi completa normalizzazione del metabolismo epatico, riducendo i grassi “tossici” e riattivando i meccanismi che permettono all’insulina di funzionare correttamente; questi cambiamenti si riflettono anche in un miglioramento visibile della struttura del fegato e dei principali indicatori metabolici.

«Questi dati mettono in discussione l’idea che il potenziale terapeutico della psilocibina sia necessariamente legato all’esperienza psichedelica – osserva Sara De Martin, corresponding author della ricerca e docente al Dipartimento di Scienze del farmaco dell’Università di Padova –. A basse dosi croniche, la psilocibina agisce come modulatore periferico del metabolismo, in particolare a livello epatico, attraverso un pathway serotoninergico distinto».

«Questi studi, condotti in un modello sperimentale nel topo, suggeriscono che la psilocibina potrebbe rappresentare una nuova cura per MASLD, il diabete di tipo 2 e l’obesità nell’uomo» aggiunge Franco Folli, corresponding author e docente al Dipartimento di Scienze della salute dell’Università di Milano.

Lo studio è stato condotto nell’ambito di una collaborazione internazionale e multi-istituzionale, guidata dall’Università di Padova e dall’Università di Milano, con l’Institute of Oncology Research (IOR) di Bellinzona, l’Azienda Socio-Sanitaria Territoriale (ASST) dei Sette Laghi di Varese e l’Università dell’Insubria, supportata da MGGM Therapeutics (New York) e Neuroarbor Therapeutics (Delaware), coinvolgendo centri di ricerca in Italia, Svizzera, Germania e Stati Uniti.

[safe_summary] => ) ) ) [field_date_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [value] => 2026-01-29T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_etichetta_box_lancio_news] => Array ( ) [field_img_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [fid] => 145761 [uid] => 26499 [filename] => psico.jpg [uri] => public://psico.jpg [filemime] => image/jpeg [filesize] => 240810 [status] => 1 [timestamp] => 1769681426 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 630 [width] => 1200 ) [height] => 630 [width] => 1200 [alt] => immagine psicadelica [title] => ) ) ) [field_link_alla_news] => Array ( ) [field_link_esterno_news] => Array ( ) [field_pagina_associata] => Array ( ) [field_link_etichetta] => Array ( ) [field_abstract_news] => Array ( [und] => Array ( [0] => Array ( [value] => Uno studio coordinato dalle Università di Padova e Milano ha dimostrato miglioramenti di obesità, insulino-resistenza e steatosi epatica con dosi non psichedeliche [format] => [safe_value] => Uno studio coordinato dalle Università di Padova e Milano ha dimostrato miglioramenti di obesità, insulino-resistenza e steatosi epatica con dosi non psichedeliche ) ) ) [field_allegato_news] => Array ( ) [field_categorie_news] => Array ( [und] => Array ( [0] => Array ( [tid] => 2264 ) [1] => Array ( [tid] => 2266 ) [2] => Array ( [tid] => 2267 ) [3] => Array ( [tid] => 2462 ) ) ) [field_pub_date] => Array ( [und] => Array ( [0] => Array ( [value] => 2026-01-29T00:00:00 [value2] => 2027-01-29T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_layout_news] => Array ( [und] => Array ( [0] => Array ( [value] => single ) ) ) [field_testo_opzionale_news] => Array ( ) [field_url_en_page] => Array ( [und] => Array ( [0] => Array ( [value] => https://www.unipd.it/news/low-dose-psilocybin-metabolic-benefits-without-psychedelic-effects [format] => [safe_value] => https://www.unipd.it/news/low-dose-psilocybin-metabolic-benefits-without-psychedelic-effects ) ) ) [field_url_en_page_label] => Array ( [und] => Array ( [0] => Array ( [value] => English version [format] => [safe_value] => English version ) ) ) [path] => Array ( [pathauto] => 1 ) [name] => rossella.vezzosi [picture] => 0 [data] => b:0; [num_revisions] => 2 [current_revision_id] => 516846 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [fid] => 145761 [uid] => 26499 [filename] => psico.jpg [uri] => public://psico.jpg [filemime] => image/jpeg [filesize] => 240810 [status] => 1 [timestamp] => 1769681426 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 630 [width] => 1200 ) [height] => 630 [width] => 1200 [alt] => immagine psicadelica [title] => ) ) [#formatter] => image [0] => Array ( [#theme] => image_formatter [#item] => Array ( [fid] => 145761 [uid] => 26499 [filename] => psico.jpg [uri] => public://psico.jpg [filemime] => image/jpeg [filesize] => 240810 [status] => 1 [timestamp] => 1769681426 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 630 [width] => 1200 ) [height] => 630 [width] => 1200 [alt] => immagine psicadelica [title] => ) [#image_style] => [#path] => ) ) [field_abstract_news] => Array ( [#theme] => field [#weight] => 0 [#title] => Abstract [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_abstract_news [#field_type] => text_long [#field_translatable] => 0 [#entity_type] => node [#bundle] => box_lancio_news [#object] => stdClass Object ( [vid] => 516846 [uid] => 26499 [title] => Psilocibina a basse dosi: benefici metabolici senza effetti psichedelici [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 127210 [type] => box_lancio_news [language] => it [created] => 1769681426 [changed] => 1769681760 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1769681760 [revision_uid] => 26499 [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

Uno studio preclinico, pubblicato sulla rivista «Pharmacological Research» e guidato dalle Università di Padova e Milano, mostra che la somministrazione cronica di dosi molto basse e non psichedeliche di psilocibina produce benefici metabolici in modelli di obesità, diabete di tipo 2 e steatosi epatica associata a disfunzione metabolica (MASLD).

In un modello di malattia metabolica indotta dalla dieta, il trattamento a lungo termine con psilocibina ha determinato una riduzione dell’aumento ponderale, un miglioramento della sensibilità insulinica, la normalizzazione della glicemia e una regressione della steatosi epatica, senza ridurre l’assunzione di cibo e senza effetti collaterali sul sistema nervoso centrale.

Attraverso analisi molecolari, lo studio ha mostrato una quasi completa normalizzazione del metabolismo epatico, riducendo i grassi “tossici” e riattivando i meccanismi che permettono all’insulina di funzionare correttamente; questi cambiamenti si riflettono anche in un miglioramento visibile della struttura del fegato e dei principali indicatori metabolici.

«Questi dati mettono in discussione l’idea che il potenziale terapeutico della psilocibina sia necessariamente legato all’esperienza psichedelica – osserva Sara De Martin, corresponding author della ricerca e docente al Dipartimento di Scienze del farmaco dell’Università di Padova –. A basse dosi croniche, la psilocibina agisce come modulatore periferico del metabolismo, in particolare a livello epatico, attraverso un pathway serotoninergico distinto».

«Questi studi, condotti in un modello sperimentale nel topo, suggeriscono che la psilocibina potrebbe rappresentare una nuova cura per MASLD, il diabete di tipo 2 e l’obesità nell’uomo» aggiunge Franco Folli, corresponding author e docente al Dipartimento di Scienze della salute dell’Università di Milano.

Lo studio è stato condotto nell’ambito di una collaborazione internazionale e multi-istituzionale, guidata dall’Università di Padova e dall’Università di Milano, con l’Institute of Oncology Research (IOR) di Bellinzona, l’Azienda Socio-Sanitaria Territoriale (ASST) dei Sette Laghi di Varese e l’Università dell’Insubria, supportata da MGGM Therapeutics (New York) e Neuroarbor Therapeutics (Delaware), coinvolgendo centri di ricerca in Italia, Svizzera, Germania e Stati Uniti.

[summary] => [format] => 2 [safe_value] =>

Uno studio preclinico, pubblicato sulla rivista «Pharmacological Research» e guidato dalle Università di Padova e Milano, mostra che la somministrazione cronica di dosi molto basse e non psichedeliche di psilocibina produce benefici metabolici in modelli di obesità, diabete di tipo 2 e steatosi epatica associata a disfunzione metabolica (MASLD).

In un modello di malattia metabolica indotta dalla dieta, il trattamento a lungo termine con psilocibina ha determinato una riduzione dell’aumento ponderale, un miglioramento della sensibilità insulinica, la normalizzazione della glicemia e una regressione della steatosi epatica, senza ridurre l’assunzione di cibo e senza effetti collaterali sul sistema nervoso centrale.

Attraverso analisi molecolari, lo studio ha mostrato una quasi completa normalizzazione del metabolismo epatico, riducendo i grassi “tossici” e riattivando i meccanismi che permettono all’insulina di funzionare correttamente; questi cambiamenti si riflettono anche in un miglioramento visibile della struttura del fegato e dei principali indicatori metabolici.

«Questi dati mettono in discussione l’idea che il potenziale terapeutico della psilocibina sia necessariamente legato all’esperienza psichedelica – osserva Sara De Martin, corresponding author della ricerca e docente al Dipartimento di Scienze del farmaco dell’Università di Padova –. A basse dosi croniche, la psilocibina agisce come modulatore periferico del metabolismo, in particolare a livello epatico, attraverso un pathway serotoninergico distinto».

«Questi studi, condotti in un modello sperimentale nel topo, suggeriscono che la psilocibina potrebbe rappresentare una nuova cura per MASLD, il diabete di tipo 2 e l’obesità nell’uomo» aggiunge Franco Folli, corresponding author e docente al Dipartimento di Scienze della salute dell’Università di Milano.

Lo studio è stato condotto nell’ambito di una collaborazione internazionale e multi-istituzionale, guidata dall’Università di Padova e dall’Università di Milano, con l’Institute of Oncology Research (IOR) di Bellinzona, l’Azienda Socio-Sanitaria Territoriale (ASST) dei Sette Laghi di Varese e l’Università dell’Insubria, supportata da MGGM Therapeutics (New York) e Neuroarbor Therapeutics (Delaware), coinvolgendo centri di ricerca in Italia, Svizzera, Germania e Stati Uniti.

[safe_summary] => ) ) ) [field_date_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [value] => 2026-01-29T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_etichetta_box_lancio_news] => Array ( ) [field_img_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [fid] => 145761 [uid] => 26499 [filename] => psico.jpg [uri] => public://psico.jpg [filemime] => image/jpeg [filesize] => 240810 [status] => 1 [timestamp] => 1769681426 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 630 [width] => 1200 ) [height] => 630 [width] => 1200 [alt] => immagine psicadelica [title] => ) ) ) [field_link_alla_news] => Array ( ) [field_link_esterno_news] => Array ( ) [field_pagina_associata] => Array ( ) [field_link_etichetta] => Array ( ) [field_abstract_news] => Array ( [und] => Array ( [0] => Array ( [value] => Uno studio coordinato dalle Università di Padova e Milano ha dimostrato miglioramenti di obesità, insulino-resistenza e steatosi epatica con dosi non psichedeliche [format] => [safe_value] => Uno studio coordinato dalle Università di Padova e Milano ha dimostrato miglioramenti di obesità, insulino-resistenza e steatosi epatica con dosi non psichedeliche ) ) ) [field_allegato_news] => Array ( ) [field_categorie_news] => Array ( [und] => Array ( [0] => Array ( [tid] => 2264 ) [1] => Array ( [tid] => 2266 ) [2] => Array ( [tid] => 2267 ) [3] => Array ( [tid] => 2462 ) ) ) [field_pub_date] => Array ( [und] => Array ( [0] => Array ( [value] => 2026-01-29T00:00:00 [value2] => 2027-01-29T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_layout_news] => Array ( [und] => Array ( [0] => Array ( [value] => single ) ) ) [field_testo_opzionale_news] => Array ( ) [field_url_en_page] => Array ( [und] => Array ( [0] => Array ( [value] => https://www.unipd.it/news/low-dose-psilocybin-metabolic-benefits-without-psychedelic-effects [format] => [safe_value] => https://www.unipd.it/news/low-dose-psilocybin-metabolic-benefits-without-psychedelic-effects ) ) ) [field_url_en_page_label] => Array ( [und] => Array ( [0] => Array ( [value] => English version [format] => [safe_value] => English version ) ) ) [path] => Array ( [pathauto] => 1 ) [name] => rossella.vezzosi [picture] => 0 [data] => b:0; [num_revisions] => 2 [current_revision_id] => 516846 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => Uno studio coordinato dalle Università di Padova e Milano ha dimostrato miglioramenti di obesità, insulino-resistenza e steatosi epatica con dosi non psichedeliche [format] => [safe_value] => Uno studio coordinato dalle Università di Padova e Milano ha dimostrato miglioramenti di obesità, insulino-resistenza e steatosi epatica con dosi non psichedeliche ) ) [#formatter] => text_default [0] => Array ( [#markup] => Uno studio coordinato dalle Università di Padova e Milano ha dimostrato miglioramenti di obesità, insulino-resistenza e steatosi epatica con dosi non psichedeliche ) ) [links] => Array ( [#theme] => links__node [#pre_render] => Array ( [0] => drupal_pre_render_links ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) [node] => Array ( [#theme] => links__node__node [#links] => Array ( [node-readmore] => Array ( [title] => Read more about Psilocibina a basse dosi: benefici metabolici senza effetti psichedelici [href] => node/127210 [html] => 1 [attributes] => Array ( [rel] => tag [title] => Psilocibina a basse dosi: benefici metabolici senza effetti psichedelici ) ) ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) ) ) [field_date_box_lancio_news] => Array ( [#theme] => field [#weight] => 1 [#title] => Data [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_date_box_lancio_news [#field_type] => date [#field_translatable] => 0 [#entity_type] => node [#bundle] => box_lancio_news [#object] => stdClass Object ( [vid] => 516846 [uid] => 26499 [title] => Psilocibina a basse dosi: benefici metabolici senza effetti psichedelici [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 127210 [type] => box_lancio_news [language] => it [created] => 1769681426 [changed] => 1769681760 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1769681760 [revision_uid] => 26499 [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

Uno studio preclinico, pubblicato sulla rivista «Pharmacological Research» e guidato dalle Università di Padova e Milano, mostra che la somministrazione cronica di dosi molto basse e non psichedeliche di psilocibina produce benefici metabolici in modelli di obesità, diabete di tipo 2 e steatosi epatica associata a disfunzione metabolica (MASLD).

In un modello di malattia metabolica indotta dalla dieta, il trattamento a lungo termine con psilocibina ha determinato una riduzione dell’aumento ponderale, un miglioramento della sensibilità insulinica, la normalizzazione della glicemia e una regressione della steatosi epatica, senza ridurre l’assunzione di cibo e senza effetti collaterali sul sistema nervoso centrale.

Attraverso analisi molecolari, lo studio ha mostrato una quasi completa normalizzazione del metabolismo epatico, riducendo i grassi “tossici” e riattivando i meccanismi che permettono all’insulina di funzionare correttamente; questi cambiamenti si riflettono anche in un miglioramento visibile della struttura del fegato e dei principali indicatori metabolici.

«Questi dati mettono in discussione l’idea che il potenziale terapeutico della psilocibina sia necessariamente legato all’esperienza psichedelica – osserva Sara De Martin, corresponding author della ricerca e docente al Dipartimento di Scienze del farmaco dell’Università di Padova –. A basse dosi croniche, la psilocibina agisce come modulatore periferico del metabolismo, in particolare a livello epatico, attraverso un pathway serotoninergico distinto».

«Questi studi, condotti in un modello sperimentale nel topo, suggeriscono che la psilocibina potrebbe rappresentare una nuova cura per MASLD, il diabete di tipo 2 e l’obesità nell’uomo» aggiunge Franco Folli, corresponding author e docente al Dipartimento di Scienze della salute dell’Università di Milano.

Lo studio è stato condotto nell’ambito di una collaborazione internazionale e multi-istituzionale, guidata dall’Università di Padova e dall’Università di Milano, con l’Institute of Oncology Research (IOR) di Bellinzona, l’Azienda Socio-Sanitaria Territoriale (ASST) dei Sette Laghi di Varese e l’Università dell’Insubria, supportata da MGGM Therapeutics (New York) e Neuroarbor Therapeutics (Delaware), coinvolgendo centri di ricerca in Italia, Svizzera, Germania e Stati Uniti.

[summary] => [format] => 2 [safe_value] =>

Uno studio preclinico, pubblicato sulla rivista «Pharmacological Research» e guidato dalle Università di Padova e Milano, mostra che la somministrazione cronica di dosi molto basse e non psichedeliche di psilocibina produce benefici metabolici in modelli di obesità, diabete di tipo 2 e steatosi epatica associata a disfunzione metabolica (MASLD).

In un modello di malattia metabolica indotta dalla dieta, il trattamento a lungo termine con psilocibina ha determinato una riduzione dell’aumento ponderale, un miglioramento della sensibilità insulinica, la normalizzazione della glicemia e una regressione della steatosi epatica, senza ridurre l’assunzione di cibo e senza effetti collaterali sul sistema nervoso centrale.

Attraverso analisi molecolari, lo studio ha mostrato una quasi completa normalizzazione del metabolismo epatico, riducendo i grassi “tossici” e riattivando i meccanismi che permettono all’insulina di funzionare correttamente; questi cambiamenti si riflettono anche in un miglioramento visibile della struttura del fegato e dei principali indicatori metabolici.

«Questi dati mettono in discussione l’idea che il potenziale terapeutico della psilocibina sia necessariamente legato all’esperienza psichedelica – osserva Sara De Martin, corresponding author della ricerca e docente al Dipartimento di Scienze del farmaco dell’Università di Padova –. A basse dosi croniche, la psilocibina agisce come modulatore periferico del metabolismo, in particolare a livello epatico, attraverso un pathway serotoninergico distinto».

«Questi studi, condotti in un modello sperimentale nel topo, suggeriscono che la psilocibina potrebbe rappresentare una nuova cura per MASLD, il diabete di tipo 2 e l’obesità nell’uomo» aggiunge Franco Folli, corresponding author e docente al Dipartimento di Scienze della salute dell’Università di Milano.

Lo studio è stato condotto nell’ambito di una collaborazione internazionale e multi-istituzionale, guidata dall’Università di Padova e dall’Università di Milano, con l’Institute of Oncology Research (IOR) di Bellinzona, l’Azienda Socio-Sanitaria Territoriale (ASST) dei Sette Laghi di Varese e l’Università dell’Insubria, supportata da MGGM Therapeutics (New York) e Neuroarbor Therapeutics (Delaware), coinvolgendo centri di ricerca in Italia, Svizzera, Germania e Stati Uniti.

[safe_summary] => ) ) ) [field_date_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [value] => 2026-01-29T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_etichetta_box_lancio_news] => Array ( ) [field_img_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [fid] => 145761 [uid] => 26499 [filename] => psico.jpg [uri] => public://psico.jpg [filemime] => image/jpeg [filesize] => 240810 [status] => 1 [timestamp] => 1769681426 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 630 [width] => 1200 ) [height] => 630 [width] => 1200 [alt] => immagine psicadelica [title] => ) ) ) [field_link_alla_news] => Array ( ) [field_link_esterno_news] => Array ( ) [field_pagina_associata] => Array ( ) [field_link_etichetta] => Array ( ) [field_abstract_news] => Array ( [und] => Array ( [0] => Array ( [value] => Uno studio coordinato dalle Università di Padova e Milano ha dimostrato miglioramenti di obesità, insulino-resistenza e steatosi epatica con dosi non psichedeliche [format] => [safe_value] => Uno studio coordinato dalle Università di Padova e Milano ha dimostrato miglioramenti di obesità, insulino-resistenza e steatosi epatica con dosi non psichedeliche ) ) ) [field_allegato_news] => Array ( ) [field_categorie_news] => Array ( [und] => Array ( [0] => Array ( [tid] => 2264 ) [1] => Array ( [tid] => 2266 ) [2] => Array ( [tid] => 2267 ) [3] => Array ( [tid] => 2462 ) ) ) [field_pub_date] => Array ( [und] => Array ( [0] => Array ( [value] => 2026-01-29T00:00:00 [value2] => 2027-01-29T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_layout_news] => Array ( [und] => Array ( [0] => Array ( [value] => single ) ) ) [field_testo_opzionale_news] => Array ( ) [field_url_en_page] => Array ( [und] => Array ( [0] => Array ( [value] => https://www.unipd.it/news/low-dose-psilocybin-metabolic-benefits-without-psychedelic-effects [format] => [safe_value] => https://www.unipd.it/news/low-dose-psilocybin-metabolic-benefits-without-psychedelic-effects ) ) ) [field_url_en_page_label] => Array ( [und] => Array ( [0] => Array ( [value] => English version [format] => [safe_value] => English version ) ) ) [path] => Array ( [pathauto] => 1 ) [name] => rossella.vezzosi [picture] => 0 [data] => b:0; [num_revisions] => 2 [current_revision_id] => 516846 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => 2026-01-29T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) [#formatter] => date_default [0] => Array ( [#markup] => Gio, 29/01/2026 ) ) )

The Care Factories

Array ( [body] => Array ( [#theme] => field [#weight] => 0 [#title] => Body [#access] => 1 [#label_display] => hidden [#view_mode] => teaser [#language] => und [#field_name] => body [#field_type] => text_with_summary [#field_translatable] => 0 [#entity_type] => node [#bundle] => box_lancio_news [#object] => stdClass Object ( [vid] => 517487 [uid] => 26499 [title] => The Care Factories [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 127209 [type] => box_lancio_news [language] => it [created] => 1769679676 [changed] => 1770374861 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1770374861 [revision_uid] => 26499 [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

Health narratives often emphasise individual responsibilities, overlooking the importance of collective factors such as the type of work and its organisation. Researchers from the "InMigrHealth - Investigating Migrants' Occupational Health" project at the Universities of Padua, Messina, and Turin (funded by the PNRR among the projects of national relevant interest) aimed to revisit the link between work and health. They did so using tools from their respective disciplines – sociology, anthropology, epidemiology, and statistics – and focusing on a highly feminised occupation with a significant presence of staff with migrant backgrounds: healthcare workers (OSS) in residential care facilities (RSA).

The video "The Care Factories," produced by SMK Factory, explores this theme through the experiences of Lukenge Lunanga, OSS and union delegate, Francesca Polizzi, OSS on union leave, and Costanza Galanti, sociologist of the project. Lukenge describes the stress and physical wear caused by working in RSAs, while Francesca highlights the need for a collective struggle to improve working conditions and criticise inadequate regional policies and collective agreements. Costanza confirms, through data collected by her research group, the link between work organisation and the negative health conditions of OSS workers.

The study, enriched by audio interviews and archival material, underscores the devastating consequences of a work organisation similar to that of a factory. In the finale, it offers a perspective of hope, suggesting that a different work organisation could improve the effectiveness and humanity of care, while also making the work of OSS workers more rewarding. The video concludes with the words of researcher Costanza Galanti, who reiterates that this is not "the only way in which healthcare services can be organised," adding: "we imagine that with a different work organisation, care could be more effective, more humane, and the work for OSS workers more rewarding."

The video production team includes Claudio Cadei, Nicola Zambelli, Luigi D'Alife, Angelica Gentilini, Costanza Galanti, and Valeria Piro. The InMigrHealth research group involves experts from the Universities of Padua, Turin, and Messina, including Valeria Piro, Francesca Alice Vianello, Camilla De Ambroggi, Noemi Martorano, Fulvio Ricceri, Alberto Bentsik, Dario Fontana, Giuliana Sanò, Veronica Buffon, and Domenica Farinella.

[summary] => [format] => 2 [safe_value] =>

Health narratives often emphasise individual responsibilities, overlooking the importance of collective factors such as the type of work and its organisation. Researchers from the "InMigrHealth - Investigating Migrants' Occupational Health" project at the Universities of Padua, Messina, and Turin (funded by the PNRR among the projects of national relevant interest) aimed to revisit the link between work and health. They did so using tools from their respective disciplines – sociology, anthropology, epidemiology, and statistics – and focusing on a highly feminised occupation with a significant presence of staff with migrant backgrounds: healthcare workers (OSS) in residential care facilities (RSA).

The video "The Care Factories," produced by SMK Factory, explores this theme through the experiences of Lukenge Lunanga, OSS and union delegate, Francesca Polizzi, OSS on union leave, and Costanza Galanti, sociologist of the project. Lukenge describes the stress and physical wear caused by working in RSAs, while Francesca highlights the need for a collective struggle to improve working conditions and criticise inadequate regional policies and collective agreements. Costanza confirms, through data collected by her research group, the link between work organisation and the negative health conditions of OSS workers.

The study, enriched by audio interviews and archival material, underscores the devastating consequences of a work organisation similar to that of a factory. In the finale, it offers a perspective of hope, suggesting that a different work organisation could improve the effectiveness and humanity of care, while also making the work of OSS workers more rewarding. The video concludes with the words of researcher Costanza Galanti, who reiterates that this is not "the only way in which healthcare services can be organised," adding: "we imagine that with a different work organisation, care could be more effective, more humane, and the work for OSS workers more rewarding."

The video production team includes Claudio Cadei, Nicola Zambelli, Luigi D'Alife, Angelica Gentilini, Costanza Galanti, and Valeria Piro. The InMigrHealth research group involves experts from the Universities of Padua, Turin, and Messina, including Valeria Piro, Francesca Alice Vianello, Camilla De Ambroggi, Noemi Martorano, Fulvio Ricceri, Alberto Bentsik, Dario Fontana, Giuliana Sanò, Veronica Buffon, and Domenica Farinella.

[safe_summary] => ) ) ) [field_date_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [value] => 2026-01-29T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_etichetta_box_lancio_news] => Array ( ) [field_img_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [fid] => 145973 [uid] => 26499 [filename] => ospedale_26.jpg [uri] => public://ospedale_26_0.jpg [filemime] => image/jpeg [filesize] => 19963 [status] => 1 [timestamp] => 1770374861 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 227 [width] => 677 ) [height] => 227 [width] => 677 [alt] => hospital ward [title] => ) ) ) [field_link_alla_news] => Array ( ) [field_link_esterno_news] => Array ( ) [field_pagina_associata] => Array ( ) [field_link_etichetta] => Array ( ) [field_abstract_news] => Array ( [und] => Array ( [0] => Array ( [value] => The "InMigrHealth" project by the Universities of Padua, Messina, and Turin, focusing on healthcare workers in residential care facilities, highlights a work organisation similar to that of a factory [format] => [safe_value] => The "InMigrHealth" project by the Universities of Padua, Messina, and Turin, focusing on healthcare workers in residential care facilities, highlights a work organisation similar to that of a factory ) ) ) [field_allegato_news] => Array ( ) [field_categorie_news] => Array ( [und] => Array ( [0] => Array ( [tid] => 2296 ) ) ) [field_pub_date] => Array ( [und] => Array ( [0] => Array ( [value] => 2026-01-29T00:00:00 [value2] => 2027-01-29T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_layout_news] => Array ( [und] => Array ( [0] => Array ( [value] => single ) ) ) [field_testo_opzionale_news] => Array ( ) [field_url_en_page] => Array ( [und] => Array ( [0] => Array ( [value] => https://www.unipd.it/news/fabbriche-cura [format] => [safe_value] => https://www.unipd.it/news/fabbriche-cura ) ) ) [field_url_en_page_label] => Array ( [und] => Array ( [0] => Array ( [value] => Versione italiana [format] => [safe_value] => Versione italiana ) ) ) [path] => Array ( [pathauto] => 1 ) [name] => rossella.vezzosi [picture] => 0 [data] => b:0; [num_revisions] => 4 [current_revision_id] => 517487 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] =>

Health narratives often emphasise individual responsibilities, overlooking the importance of collective factors such as the type of work and its organisation. Researchers from the "InMigrHealth - Investigating Migrants' Occupational Health" project at the Universities of Padua, Messina, and Turin (funded by the PNRR among the projects of national relevant interest) aimed to revisit the link between work and health. They did so using tools from their respective disciplines – sociology, anthropology, epidemiology, and statistics – and focusing on a highly feminised occupation with a significant presence of staff with migrant backgrounds: healthcare workers (OSS) in residential care facilities (RSA).

The video "The Care Factories," produced by SMK Factory, explores this theme through the experiences of Lukenge Lunanga, OSS and union delegate, Francesca Polizzi, OSS on union leave, and Costanza Galanti, sociologist of the project. Lukenge describes the stress and physical wear caused by working in RSAs, while Francesca highlights the need for a collective struggle to improve working conditions and criticise inadequate regional policies and collective agreements. Costanza confirms, through data collected by her research group, the link between work organisation and the negative health conditions of OSS workers.

The study, enriched by audio interviews and archival material, underscores the devastating consequences of a work organisation similar to that of a factory. In the finale, it offers a perspective of hope, suggesting that a different work organisation could improve the effectiveness and humanity of care, while also making the work of OSS workers more rewarding. The video concludes with the words of researcher Costanza Galanti, who reiterates that this is not "the only way in which healthcare services can be organised," adding: "we imagine that with a different work organisation, care could be more effective, more humane, and the work for OSS workers more rewarding."

The video production team includes Claudio Cadei, Nicola Zambelli, Luigi D'Alife, Angelica Gentilini, Costanza Galanti, and Valeria Piro. The InMigrHealth research group involves experts from the Universities of Padua, Turin, and Messina, including Valeria Piro, Francesca Alice Vianello, Camilla De Ambroggi, Noemi Martorano, Fulvio Ricceri, Alberto Bentsik, Dario Fontana, Giuliana Sanò, Veronica Buffon, and Domenica Farinella.

[summary] => [format] => 2 [safe_value] =>

Health narratives often emphasise individual responsibilities, overlooking the importance of collective factors such as the type of work and its organisation. Researchers from the "InMigrHealth - Investigating Migrants' Occupational Health" project at the Universities of Padua, Messina, and Turin (funded by the PNRR among the projects of national relevant interest) aimed to revisit the link between work and health. They did so using tools from their respective disciplines – sociology, anthropology, epidemiology, and statistics – and focusing on a highly feminised occupation with a significant presence of staff with migrant backgrounds: healthcare workers (OSS) in residential care facilities (RSA).

The video "The Care Factories," produced by SMK Factory, explores this theme through the experiences of Lukenge Lunanga, OSS and union delegate, Francesca Polizzi, OSS on union leave, and Costanza Galanti, sociologist of the project. Lukenge describes the stress and physical wear caused by working in RSAs, while Francesca highlights the need for a collective struggle to improve working conditions and criticise inadequate regional policies and collective agreements. Costanza confirms, through data collected by her research group, the link between work organisation and the negative health conditions of OSS workers.

The study, enriched by audio interviews and archival material, underscores the devastating consequences of a work organisation similar to that of a factory. In the finale, it offers a perspective of hope, suggesting that a different work organisation could improve the effectiveness and humanity of care, while also making the work of OSS workers more rewarding. The video concludes with the words of researcher Costanza Galanti, who reiterates that this is not "the only way in which healthcare services can be organised," adding: "we imagine that with a different work organisation, care could be more effective, more humane, and the work for OSS workers more rewarding."

The video production team includes Claudio Cadei, Nicola Zambelli, Luigi D'Alife, Angelica Gentilini, Costanza Galanti, and Valeria Piro. The InMigrHealth research group involves experts from the Universities of Padua, Turin, and Messina, including Valeria Piro, Francesca Alice Vianello, Camilla De Ambroggi, Noemi Martorano, Fulvio Ricceri, Alberto Bentsik, Dario Fontana, Giuliana Sanò, Veronica Buffon, and Domenica Farinella.

[safe_summary] => ) ) [#formatter] => text_summary_or_trimmed [0] => Array ( [#markup] =>

Health narratives often emphasise individual responsibilities, overlooking the importance of collective factors such as the type of work and its organisation. Researchers from the "InMigrHealth - Investigating Migrants' Occupational Health" project at the Universities of Padua, Messina, and Turin (funded by the PNRR among the projects of national relevant interest) aimed to revisit the link between work and health.

) ) [field_img_box_lancio_news] => Array ( [#theme] => field [#weight] => 0 [#title] => Immagine [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_img_box_lancio_news [#field_type] => image [#field_translatable] => 0 [#entity_type] => node [#bundle] => box_lancio_news [#object] => stdClass Object ( [vid] => 517487 [uid] => 26499 [title] => The Care Factories [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 127209 [type] => box_lancio_news [language] => it [created] => 1769679676 [changed] => 1770374861 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1770374861 [revision_uid] => 26499 [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

Health narratives often emphasise individual responsibilities, overlooking the importance of collective factors such as the type of work and its organisation. Researchers from the "InMigrHealth - Investigating Migrants' Occupational Health" project at the Universities of Padua, Messina, and Turin (funded by the PNRR among the projects of national relevant interest) aimed to revisit the link between work and health. They did so using tools from their respective disciplines – sociology, anthropology, epidemiology, and statistics – and focusing on a highly feminised occupation with a significant presence of staff with migrant backgrounds: healthcare workers (OSS) in residential care facilities (RSA).

The video "The Care Factories," produced by SMK Factory, explores this theme through the experiences of Lukenge Lunanga, OSS and union delegate, Francesca Polizzi, OSS on union leave, and Costanza Galanti, sociologist of the project. Lukenge describes the stress and physical wear caused by working in RSAs, while Francesca highlights the need for a collective struggle to improve working conditions and criticise inadequate regional policies and collective agreements. Costanza confirms, through data collected by her research group, the link between work organisation and the negative health conditions of OSS workers.

The study, enriched by audio interviews and archival material, underscores the devastating consequences of a work organisation similar to that of a factory. In the finale, it offers a perspective of hope, suggesting that a different work organisation could improve the effectiveness and humanity of care, while also making the work of OSS workers more rewarding. The video concludes with the words of researcher Costanza Galanti, who reiterates that this is not "the only way in which healthcare services can be organised," adding: "we imagine that with a different work organisation, care could be more effective, more humane, and the work for OSS workers more rewarding."

The video production team includes Claudio Cadei, Nicola Zambelli, Luigi D'Alife, Angelica Gentilini, Costanza Galanti, and Valeria Piro. The InMigrHealth research group involves experts from the Universities of Padua, Turin, and Messina, including Valeria Piro, Francesca Alice Vianello, Camilla De Ambroggi, Noemi Martorano, Fulvio Ricceri, Alberto Bentsik, Dario Fontana, Giuliana Sanò, Veronica Buffon, and Domenica Farinella.

[summary] => [format] => 2 [safe_value] =>

Health narratives often emphasise individual responsibilities, overlooking the importance of collective factors such as the type of work and its organisation. Researchers from the "InMigrHealth - Investigating Migrants' Occupational Health" project at the Universities of Padua, Messina, and Turin (funded by the PNRR among the projects of national relevant interest) aimed to revisit the link between work and health. They did so using tools from their respective disciplines – sociology, anthropology, epidemiology, and statistics – and focusing on a highly feminised occupation with a significant presence of staff with migrant backgrounds: healthcare workers (OSS) in residential care facilities (RSA).

The video "The Care Factories," produced by SMK Factory, explores this theme through the experiences of Lukenge Lunanga, OSS and union delegate, Francesca Polizzi, OSS on union leave, and Costanza Galanti, sociologist of the project. Lukenge describes the stress and physical wear caused by working in RSAs, while Francesca highlights the need for a collective struggle to improve working conditions and criticise inadequate regional policies and collective agreements. Costanza confirms, through data collected by her research group, the link between work organisation and the negative health conditions of OSS workers.

The study, enriched by audio interviews and archival material, underscores the devastating consequences of a work organisation similar to that of a factory. In the finale, it offers a perspective of hope, suggesting that a different work organisation could improve the effectiveness and humanity of care, while also making the work of OSS workers more rewarding. The video concludes with the words of researcher Costanza Galanti, who reiterates that this is not "the only way in which healthcare services can be organised," adding: "we imagine that with a different work organisation, care could be more effective, more humane, and the work for OSS workers more rewarding."

The video production team includes Claudio Cadei, Nicola Zambelli, Luigi D'Alife, Angelica Gentilini, Costanza Galanti, and Valeria Piro. The InMigrHealth research group involves experts from the Universities of Padua, Turin, and Messina, including Valeria Piro, Francesca Alice Vianello, Camilla De Ambroggi, Noemi Martorano, Fulvio Ricceri, Alberto Bentsik, Dario Fontana, Giuliana Sanò, Veronica Buffon, and Domenica Farinella.

[safe_summary] => ) ) ) [field_date_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [value] => 2026-01-29T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_etichetta_box_lancio_news] => Array ( ) [field_img_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [fid] => 145973 [uid] => 26499 [filename] => ospedale_26.jpg [uri] => public://ospedale_26_0.jpg [filemime] => image/jpeg [filesize] => 19963 [status] => 1 [timestamp] => 1770374861 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 227 [width] => 677 ) [height] => 227 [width] => 677 [alt] => hospital ward [title] => ) ) ) [field_link_alla_news] => Array ( ) [field_link_esterno_news] => Array ( ) [field_pagina_associata] => Array ( ) [field_link_etichetta] => Array ( ) [field_abstract_news] => Array ( [und] => Array ( [0] => Array ( [value] => The "InMigrHealth" project by the Universities of Padua, Messina, and Turin, focusing on healthcare workers in residential care facilities, highlights a work organisation similar to that of a factory [format] => [safe_value] => The "InMigrHealth" project by the Universities of Padua, Messina, and Turin, focusing on healthcare workers in residential care facilities, highlights a work organisation similar to that of a factory ) ) ) [field_allegato_news] => Array ( ) [field_categorie_news] => Array ( [und] => Array ( [0] => Array ( [tid] => 2296 ) ) ) [field_pub_date] => Array ( [und] => Array ( [0] => Array ( [value] => 2026-01-29T00:00:00 [value2] => 2027-01-29T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_layout_news] => Array ( [und] => Array ( [0] => Array ( [value] => single ) ) ) [field_testo_opzionale_news] => Array ( ) [field_url_en_page] => Array ( [und] => Array ( [0] => Array ( [value] => https://www.unipd.it/news/fabbriche-cura [format] => [safe_value] => https://www.unipd.it/news/fabbriche-cura ) ) ) [field_url_en_page_label] => Array ( [und] => Array ( [0] => Array ( [value] => Versione italiana [format] => [safe_value] => Versione italiana ) ) ) [path] => Array ( [pathauto] => 1 ) [name] => rossella.vezzosi [picture] => 0 [data] => b:0; [num_revisions] => 4 [current_revision_id] => 517487 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [fid] => 145973 [uid] => 26499 [filename] => ospedale_26.jpg [uri] => public://ospedale_26_0.jpg [filemime] => image/jpeg [filesize] => 19963 [status] => 1 [timestamp] => 1770374861 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 227 [width] => 677 ) [height] => 227 [width] => 677 [alt] => hospital ward [title] => ) ) [#formatter] => image [0] => Array ( [#theme] => image_formatter [#item] => Array ( [fid] => 145973 [uid] => 26499 [filename] => ospedale_26.jpg [uri] => public://ospedale_26_0.jpg [filemime] => image/jpeg [filesize] => 19963 [status] => 1 [timestamp] => 1770374861 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 227 [width] => 677 ) [height] => 227 [width] => 677 [alt] => hospital ward [title] => ) [#image_style] => [#path] => ) ) [field_abstract_news] => Array ( [#theme] => field [#weight] => 0 [#title] => Abstract [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_abstract_news [#field_type] => text_long [#field_translatable] => 0 [#entity_type] => node [#bundle] => box_lancio_news [#object] => stdClass Object ( [vid] => 517487 [uid] => 26499 [title] => The Care Factories [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 127209 [type] => box_lancio_news [language] => it [created] => 1769679676 [changed] => 1770374861 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1770374861 [revision_uid] => 26499 [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

Health narratives often emphasise individual responsibilities, overlooking the importance of collective factors such as the type of work and its organisation. Researchers from the "InMigrHealth - Investigating Migrants' Occupational Health" project at the Universities of Padua, Messina, and Turin (funded by the PNRR among the projects of national relevant interest) aimed to revisit the link between work and health. They did so using tools from their respective disciplines – sociology, anthropology, epidemiology, and statistics – and focusing on a highly feminised occupation with a significant presence of staff with migrant backgrounds: healthcare workers (OSS) in residential care facilities (RSA).

The video "The Care Factories," produced by SMK Factory, explores this theme through the experiences of Lukenge Lunanga, OSS and union delegate, Francesca Polizzi, OSS on union leave, and Costanza Galanti, sociologist of the project. Lukenge describes the stress and physical wear caused by working in RSAs, while Francesca highlights the need for a collective struggle to improve working conditions and criticise inadequate regional policies and collective agreements. Costanza confirms, through data collected by her research group, the link between work organisation and the negative health conditions of OSS workers.

The study, enriched by audio interviews and archival material, underscores the devastating consequences of a work organisation similar to that of a factory. In the finale, it offers a perspective of hope, suggesting that a different work organisation could improve the effectiveness and humanity of care, while also making the work of OSS workers more rewarding. The video concludes with the words of researcher Costanza Galanti, who reiterates that this is not "the only way in which healthcare services can be organised," adding: "we imagine that with a different work organisation, care could be more effective, more humane, and the work for OSS workers more rewarding."

The video production team includes Claudio Cadei, Nicola Zambelli, Luigi D'Alife, Angelica Gentilini, Costanza Galanti, and Valeria Piro. The InMigrHealth research group involves experts from the Universities of Padua, Turin, and Messina, including Valeria Piro, Francesca Alice Vianello, Camilla De Ambroggi, Noemi Martorano, Fulvio Ricceri, Alberto Bentsik, Dario Fontana, Giuliana Sanò, Veronica Buffon, and Domenica Farinella.

[summary] => [format] => 2 [safe_value] =>

Health narratives often emphasise individual responsibilities, overlooking the importance of collective factors such as the type of work and its organisation. Researchers from the "InMigrHealth - Investigating Migrants' Occupational Health" project at the Universities of Padua, Messina, and Turin (funded by the PNRR among the projects of national relevant interest) aimed to revisit the link between work and health. They did so using tools from their respective disciplines – sociology, anthropology, epidemiology, and statistics – and focusing on a highly feminised occupation with a significant presence of staff with migrant backgrounds: healthcare workers (OSS) in residential care facilities (RSA).

The video "The Care Factories," produced by SMK Factory, explores this theme through the experiences of Lukenge Lunanga, OSS and union delegate, Francesca Polizzi, OSS on union leave, and Costanza Galanti, sociologist of the project. Lukenge describes the stress and physical wear caused by working in RSAs, while Francesca highlights the need for a collective struggle to improve working conditions and criticise inadequate regional policies and collective agreements. Costanza confirms, through data collected by her research group, the link between work organisation and the negative health conditions of OSS workers.

The study, enriched by audio interviews and archival material, underscores the devastating consequences of a work organisation similar to that of a factory. In the finale, it offers a perspective of hope, suggesting that a different work organisation could improve the effectiveness and humanity of care, while also making the work of OSS workers more rewarding. The video concludes with the words of researcher Costanza Galanti, who reiterates that this is not "the only way in which healthcare services can be organised," adding: "we imagine that with a different work organisation, care could be more effective, more humane, and the work for OSS workers more rewarding."

The video production team includes Claudio Cadei, Nicola Zambelli, Luigi D'Alife, Angelica Gentilini, Costanza Galanti, and Valeria Piro. The InMigrHealth research group involves experts from the Universities of Padua, Turin, and Messina, including Valeria Piro, Francesca Alice Vianello, Camilla De Ambroggi, Noemi Martorano, Fulvio Ricceri, Alberto Bentsik, Dario Fontana, Giuliana Sanò, Veronica Buffon, and Domenica Farinella.

[safe_summary] => ) ) ) [field_date_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [value] => 2026-01-29T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_etichetta_box_lancio_news] => Array ( ) [field_img_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [fid] => 145973 [uid] => 26499 [filename] => ospedale_26.jpg [uri] => public://ospedale_26_0.jpg [filemime] => image/jpeg [filesize] => 19963 [status] => 1 [timestamp] => 1770374861 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 227 [width] => 677 ) [height] => 227 [width] => 677 [alt] => hospital ward [title] => ) ) ) [field_link_alla_news] => Array ( ) [field_link_esterno_news] => Array ( ) [field_pagina_associata] => Array ( ) [field_link_etichetta] => Array ( ) [field_abstract_news] => Array ( [und] => Array ( [0] => Array ( [value] => The "InMigrHealth" project by the Universities of Padua, Messina, and Turin, focusing on healthcare workers in residential care facilities, highlights a work organisation similar to that of a factory [format] => [safe_value] => The "InMigrHealth" project by the Universities of Padua, Messina, and Turin, focusing on healthcare workers in residential care facilities, highlights a work organisation similar to that of a factory ) ) ) [field_allegato_news] => Array ( ) [field_categorie_news] => Array ( [und] => Array ( [0] => Array ( [tid] => 2296 ) ) ) [field_pub_date] => Array ( [und] => Array ( [0] => Array ( [value] => 2026-01-29T00:00:00 [value2] => 2027-01-29T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_layout_news] => Array ( [und] => Array ( [0] => Array ( [value] => single ) ) ) [field_testo_opzionale_news] => Array ( ) [field_url_en_page] => Array ( [und] => Array ( [0] => Array ( [value] => https://www.unipd.it/news/fabbriche-cura [format] => [safe_value] => https://www.unipd.it/news/fabbriche-cura ) ) ) [field_url_en_page_label] => Array ( [und] => Array ( [0] => Array ( [value] => Versione italiana [format] => [safe_value] => Versione italiana ) ) ) [path] => Array ( [pathauto] => 1 ) [name] => rossella.vezzosi [picture] => 0 [data] => b:0; [num_revisions] => 4 [current_revision_id] => 517487 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => The "InMigrHealth" project by the Universities of Padua, Messina, and Turin, focusing on healthcare workers in residential care facilities, highlights a work organisation similar to that of a factory [format] => [safe_value] => The "InMigrHealth" project by the Universities of Padua, Messina, and Turin, focusing on healthcare workers in residential care facilities, highlights a work organisation similar to that of a factory ) ) [#formatter] => text_default [0] => Array ( [#markup] => The "InMigrHealth" project by the Universities of Padua, Messina, and Turin, focusing on healthcare workers in residential care facilities, highlights a work organisation similar to that of a factory ) ) [links] => Array ( [#theme] => links__node [#pre_render] => Array ( [0] => drupal_pre_render_links ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) [node] => Array ( [#theme] => links__node__node [#links] => Array ( [node-readmore] => Array ( [title] => Read more about The Care Factories [href] => node/127209 [html] => 1 [attributes] => Array ( [rel] => tag [title] => The Care Factories ) ) ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) ) ) [field_date_box_lancio_news] => Array ( [#theme] => field [#weight] => 1 [#title] => Data [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_date_box_lancio_news [#field_type] => date [#field_translatable] => 0 [#entity_type] => node [#bundle] => box_lancio_news [#object] => stdClass Object ( [vid] => 517487 [uid] => 26499 [title] => The Care Factories [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 127209 [type] => box_lancio_news [language] => it [created] => 1769679676 [changed] => 1770374861 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1770374861 [revision_uid] => 26499 [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

Health narratives often emphasise individual responsibilities, overlooking the importance of collective factors such as the type of work and its organisation. Researchers from the "InMigrHealth - Investigating Migrants' Occupational Health" project at the Universities of Padua, Messina, and Turin (funded by the PNRR among the projects of national relevant interest) aimed to revisit the link between work and health. They did so using tools from their respective disciplines – sociology, anthropology, epidemiology, and statistics – and focusing on a highly feminised occupation with a significant presence of staff with migrant backgrounds: healthcare workers (OSS) in residential care facilities (RSA).

The video "The Care Factories," produced by SMK Factory, explores this theme through the experiences of Lukenge Lunanga, OSS and union delegate, Francesca Polizzi, OSS on union leave, and Costanza Galanti, sociologist of the project. Lukenge describes the stress and physical wear caused by working in RSAs, while Francesca highlights the need for a collective struggle to improve working conditions and criticise inadequate regional policies and collective agreements. Costanza confirms, through data collected by her research group, the link between work organisation and the negative health conditions of OSS workers.

The study, enriched by audio interviews and archival material, underscores the devastating consequences of a work organisation similar to that of a factory. In the finale, it offers a perspective of hope, suggesting that a different work organisation could improve the effectiveness and humanity of care, while also making the work of OSS workers more rewarding. The video concludes with the words of researcher Costanza Galanti, who reiterates that this is not "the only way in which healthcare services can be organised," adding: "we imagine that with a different work organisation, care could be more effective, more humane, and the work for OSS workers more rewarding."

The video production team includes Claudio Cadei, Nicola Zambelli, Luigi D'Alife, Angelica Gentilini, Costanza Galanti, and Valeria Piro. The InMigrHealth research group involves experts from the Universities of Padua, Turin, and Messina, including Valeria Piro, Francesca Alice Vianello, Camilla De Ambroggi, Noemi Martorano, Fulvio Ricceri, Alberto Bentsik, Dario Fontana, Giuliana Sanò, Veronica Buffon, and Domenica Farinella.

[summary] => [format] => 2 [safe_value] =>

Health narratives often emphasise individual responsibilities, overlooking the importance of collective factors such as the type of work and its organisation. Researchers from the "InMigrHealth - Investigating Migrants' Occupational Health" project at the Universities of Padua, Messina, and Turin (funded by the PNRR among the projects of national relevant interest) aimed to revisit the link between work and health. They did so using tools from their respective disciplines – sociology, anthropology, epidemiology, and statistics – and focusing on a highly feminised occupation with a significant presence of staff with migrant backgrounds: healthcare workers (OSS) in residential care facilities (RSA).

The video "The Care Factories," produced by SMK Factory, explores this theme through the experiences of Lukenge Lunanga, OSS and union delegate, Francesca Polizzi, OSS on union leave, and Costanza Galanti, sociologist of the project. Lukenge describes the stress and physical wear caused by working in RSAs, while Francesca highlights the need for a collective struggle to improve working conditions and criticise inadequate regional policies and collective agreements. Costanza confirms, through data collected by her research group, the link between work organisation and the negative health conditions of OSS workers.

The study, enriched by audio interviews and archival material, underscores the devastating consequences of a work organisation similar to that of a factory. In the finale, it offers a perspective of hope, suggesting that a different work organisation could improve the effectiveness and humanity of care, while also making the work of OSS workers more rewarding. The video concludes with the words of researcher Costanza Galanti, who reiterates that this is not "the only way in which healthcare services can be organised," adding: "we imagine that with a different work organisation, care could be more effective, more humane, and the work for OSS workers more rewarding."

The video production team includes Claudio Cadei, Nicola Zambelli, Luigi D'Alife, Angelica Gentilini, Costanza Galanti, and Valeria Piro. The InMigrHealth research group involves experts from the Universities of Padua, Turin, and Messina, including Valeria Piro, Francesca Alice Vianello, Camilla De Ambroggi, Noemi Martorano, Fulvio Ricceri, Alberto Bentsik, Dario Fontana, Giuliana Sanò, Veronica Buffon, and Domenica Farinella.

[safe_summary] => ) ) ) [field_date_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [value] => 2026-01-29T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_etichetta_box_lancio_news] => Array ( ) [field_img_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [fid] => 145973 [uid] => 26499 [filename] => ospedale_26.jpg [uri] => public://ospedale_26_0.jpg [filemime] => image/jpeg [filesize] => 19963 [status] => 1 [timestamp] => 1770374861 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 227 [width] => 677 ) [height] => 227 [width] => 677 [alt] => hospital ward [title] => ) ) ) [field_link_alla_news] => Array ( ) [field_link_esterno_news] => Array ( ) [field_pagina_associata] => Array ( ) [field_link_etichetta] => Array ( ) [field_abstract_news] => Array ( [und] => Array ( [0] => Array ( [value] => The "InMigrHealth" project by the Universities of Padua, Messina, and Turin, focusing on healthcare workers in residential care facilities, highlights a work organisation similar to that of a factory [format] => [safe_value] => The "InMigrHealth" project by the Universities of Padua, Messina, and Turin, focusing on healthcare workers in residential care facilities, highlights a work organisation similar to that of a factory ) ) ) [field_allegato_news] => Array ( ) [field_categorie_news] => Array ( [und] => Array ( [0] => Array ( [tid] => 2296 ) ) ) [field_pub_date] => Array ( [und] => Array ( [0] => Array ( [value] => 2026-01-29T00:00:00 [value2] => 2027-01-29T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_layout_news] => Array ( [und] => Array ( [0] => Array ( [value] => single ) ) ) [field_testo_opzionale_news] => Array ( ) [field_url_en_page] => Array ( [und] => Array ( [0] => Array ( [value] => https://www.unipd.it/news/fabbriche-cura [format] => [safe_value] => https://www.unipd.it/news/fabbriche-cura ) ) ) [field_url_en_page_label] => Array ( [und] => Array ( [0] => Array ( [value] => Versione italiana [format] => [safe_value] => Versione italiana ) ) ) [path] => Array ( [pathauto] => 1 ) [name] => rossella.vezzosi [picture] => 0 [data] => b:0; [num_revisions] => 4 [current_revision_id] => 517487 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => 2026-01-29T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) [#formatter] => date_default [0] => Array ( [#markup] => Gio, 29/01/2026 ) ) )

Pagine